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Summary 
 Iron plays a critical role as an oxygen carrier in hemoglobin as well as a 
constituent of iron-sulfur clusters. Increasing evidence suggests that mechanisms 
maintaining iron homeostasis cross-talk to intermediary metabolism. The liver 
hormone hepcidin is the key regulator of systemic iron metabolism. Hepcidin 
transcriptional control is linked to the nutrient-sensing mTOR pathway, proliferative 
signals, gluconeogenic responses during starvation and hormones that modulate 
energy metabolism. The aim of my PhD project was to investigate links between 
hepcidin regulation and cellular metabolism. My work describes for the first time that 
citrate metabolism controls hepcidin expression.    
 A previously reported genome-wide RNAi screen generated a first 
comprehensive atlas of hepatocytic hepcidin regulators. To study metabolic signals 
that control hepcidin expression, I selected putative hepcidin regulators from the 
screening data, noting that several are specifically involved in citrate metabolism. I 
show that the siRNA-mediated knockdown of the enzymes that catalyze citrate-
consuming reactions ACO1 (cytosolic aconitase), ACO2 (mitochondrial aconitase) 
and ACLY (ATP citrate lyase), as well as the inhibition of their enzymatic activities 
by small molecules, increases hepcidin mRNA expression in primary murine 
hepatocytes (PMH). Treatment of PMH with citrate furthermore results in the 
increase of citrate in cells and increased hepcidin expression. I further demonstrate 
that citrate acts intracellularly to regulate hepcidin via the BMP/SMAD signaling 
pathway. Injection of citrate into the tail vein of mice supports my findings that citrate 
increase in the liver augments hepcidin expression as well as the activity of 
BMP/SMAD signaling also in vivo.  
 All together, my results uncover the cross-talk between iron homeostasis and 
intermediary metabolism, and may help to explain why iron levels are altered in 
several metabolic disorders.  
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Zussamenfassung 
 Eisen ist ein essentieller Bestandteil von Enzymen, die am Zellstoffwechsel 
beteiligt sind. Beispiele hierfür sind die Cytochrom-c-Oxidase, die Fettsäure-
Desaturase, die Lipoxygenase sowie der Komplex I der Atmungskette. Der 
systemische Eisenstoffwechsel wird maßgeblich durch das Leberhormon Hepcidin 
reguliert. Es gibt Hinweise, dass der Mechanismus, der die Eisenhomöostase 
aufrechterhält, funktionell mit dem intermediären Stoffwechsel verknüpft ist. Die 
Hepcidin Transkription wird reguliert durch den mTOR Signalweg, 
Proliferationssignale, die Reaktion der Glykolyse auf Nährstoffmangel sowie durch 
Hormone, die den Energiestoffwechsel modulieren. Das Ziel meiner Doktorarbeit war 
es, eine funktionelle Verknüpfungen zwischen der Hepcidinregulation und dem 
Zellstoffwechsel zu untersuchen. Meine Ergebnisse zeigen, dass Zitrat die Expression 
von Hepcidin kontrolliert.   
 Ein genomweiter RNAi Screen, welcher einen ersten umfassenden Atlas 
hepatozytärer Regulatoren des Hepcidins generierte, stellte eine wichtige Grundlage 
für meine Doktorarbeit dar. Um metabolische Signale zu identifizieren, die die 
Expression von Hepcidin kontrollieren, fokussierte ich meine experimentelle Arbeit 
auf Hepcidinregulatoren, die speziell in den Zitratzyklus involviert sind. Ich konnte 
zeigen, dass sowohl der siRNA vermittelte ‚knockdown‘ der Enzyme ACO1 
(zytosolische Aconitase), ACO2 (mitochondriale Aconitase) and ACLY (ATP-Citrat-
Lyase), welche Reaktionen des Zitratzyklus katalysieren, als auch die Hemmung ihrer 
enzymatischen Aktivität, die Expression von Hepcidin mRNA in primären, murinen 
Hepatozyten (PMH) steigern. Des Weiteren führt eine Behandlung der PMHs mit 
Zitrat zu einer Akkumulation von Zitrat in den Zellen und einer gesteigerten 
Expression von Hepcidin. Weiterhin zeigen meine Arbeiten, dass Zitrat intrazellulär 
die Regulation von Hepcidin mittels des BMP/SMAD Signalweges bewirkt. Die 
Injektion von Zitrat in die Kaudalvene von Mäusen unterstützt meine zellulären 
Befunde insoweit, als dass dieses sich in der Leber anreichert, die Aktivität des 
BMP/SMAD Signalweges in vivo erhöht sowie die Expression von Hepcidin steigert.   
 vi 
 Zusammenfassend zeigen meine Ergebnisse ein Zusammenspiel der 
Eisenhomöostase und des intermediären Stoffwechsels, welches dazu beitragen kann, 
dass der Eisenspiegel bei häufigen Stoffwechselerkrankungen verändert ist.  
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1 
1 Introduction 
1.1 Iron Metabolism 
1.1.1 The Yin and Yang of Iron 
 Iron is one of the most abundant elements in the Earth's crust and essential for 
almost all forms of life. Its ability to shift between different oxidation states (-2 to +6) 
makes iron a highly versatile metal, suitable for numerous biochemical reactions 
(reviewed in [1]). As a constituent of heme, iron is necessary for oxygen transport and 
storage (in hemoglobin (Hb) and myoglobin respectively), and required for the 
electron transport chain (cytochrome P450) and energy production (cytochrome C and 
cytochrome C oxidase). In non-heme iron-containing proteins, iron is essential for 
oxygen sensing (hypoxia-inducible factor prolyl-hydroxylases), DNA synthesis 
(ribonucleotide reductase), protein metabolism (amino-acid oxidases), as well as for 
fatty acid biosynthesis (fatty acid desaturases) and metabolism of eicosanoids 
(lipoxygenases). In the mitochondrial complex I, iron-sulfur (Fe-S) clusters are 
crucial for energy production (reviewed [2]). The fluctuation between oxidation states 
not only allows iron to participate in vital reactions, but it also potentiates the 
generation of free radicals from superoxide and hydrogen peroxide (Fenton's 
reaction). These reactive oxygen species induce protein, lipid and DNA damage [3]. 
Since iron is both essential and toxic to cells, organisms have to efficiently regulate 
iron in order to meet the metabolic demand whilst preventing iron excess. 
 
1.1.2 Iron Distribution and Utilization 
 The body of a healthy human adult contains an average of 3-5 g of iron, 
distributed among different cell types. In the blood, 2.5 g of iron are present in 
erythrocytes (in hemoglobin) and 2-4 mg circulate bound to the high affinity iron 
plasma protein transferrin (Tf). Macrophages recycle 20 mg of iron daily from 
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senescent or damaged erythrocytes, which is later used for a new process of 
erythropoiesis. In cells, 5 mg of iron are utilized as a cofactor for iron-containing 
proteins. The human body looses 1-2 mg of iron a day due to bleeding, sweating, 
epithelial cell desquamation and urinary excretion, however, there is no controlled 
mechanism for iron elimination. These iron losses are then compensated by dietary 
iron absorption - which is a highly regulated process (reviewed in [4, 5]).  
 Duodenal enterocytes are responsible for taking up dietary iron. The inorganic 
iron (mostly ferric iron (Fe3+)) is reduced to ferrous iron (Fe2+) by the ferrireductase 
duodenal cytochrome B (Dcytb) [6] at the apical membrane side. The iron is then 
imported to the cytoplasm by the divalent metal transporter 1 (DMT1) [7]. The 
organic iron in the form of heme is absorbed by the enterocytes [8, 9] and then 
released from heme by the action of hemoxygenase I (HO1) [10]. The mechanism of 
heme absorption by the enterocytes is not yet completely understood. In the 
cytoplasm, the iron that is not used immediately for the cellular metabolism (labile 
iron pool or LIP) is delivered by the chaperone poly (rC)-binding protein 1 [11] to 
ferritin for storage. Ferritin is a hollow protein composed of several light and heavy 
chains which can store a high amount of iron. The heavy chains of ferritin are 
important for oxidation of ferrous iron into ferric iron for storage, whereas the light 
chains support the formation of the core of the Fe3+ complexes inside ferritin 
(reviewed in [12]). To supply iron when needed, ferritin undergoes lysosomal 
degradation resulting in iron release [13]. The free iron is then exported into the blood 
by ferroportin (FPN), the only-known iron exporter [14], which is located at the 
basolateral membrane of enterocytes [15]. The iron export from enterocytes to the 
blood stream by ferroportin and subsequent loading onto transferrin (Tf) is dependent 
upon the oxidation of Fe2+ to Fe3+ by the ferroxidase hephaestin [16] (Figure 1.1). Iron 
bound to transferrin can be carried to all tissues to be used or stored.  
 The uptake of iron bound to transferrin is mediated by the transferrin receptor 
1 (TfR1) [17]. When transferrin binds to TfR1, the complex undergoes clathrin-
mediated endocytosis and the acidification of the vesicle allows iron to be released 
from transferrin. Iron is then reduced to Fe2+ by the ferrireductase STEAP3 [18] and 
exported out of the endosome by DMT1 [19], while transferrin and TfR1 are recycled 
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to the plasma membrane for a new round of iron transport and uptake [20] (Figure 
1.1).  
 
      
 
Figure 1.1: Cell types involved in iron uptake, storage and recycling. 
Dietary uptake: Duodenal enterocytes are responsible for taking up dietary organic and 
inorganic iron. Inorganic iron (ferric iron, Fe3+) is reduced to Fe2+ (ferrous iron) by duodenal 
cytochrome b (Dcytb) at the apical membrane of enterocytes and transported into the cell by 
the divalent metal transporter 1 (DMT1). The iron that is not used for metabolic processes is 
stored in ferritin until it is required, whereupon it is exported into the blood via FPN. 
Hephaestin oxidizes Fe2+ into Fe3+ allowing iron to be loaded into transferrin (Tf) where it can 
be delivered to cells. Transferrin delivers iron to sites where it is needed or stored. It is not 
known how heme iron is absorbed by enterocytes. By the action of homoxygenase 1 (HO1), 
iron is released from heme and contributes to the labile-iron pool (LIP).  
Iron storage: Hepatocytes are able to store a large amount of iron. Iron is taken up via the 
TfR1. The iron bound Tf binds to the TfR1 and this complex undergoes endocytosis. The iron 
is released from transferrin and exported from the endosome to the cytoplasm via DMT1. In 
the cytoplasm, iron can be either utilized, stored in ferritin or exported to the blood via FPN. 
Ceruloplasmin oxidizes Fe2+ to Fe3+ in order for iron to be loaded into transferrin. The 
ZRT/IRT-like protein 14 (ZIP14) and its partner ferrireductase prion-protein (PRNP) mediate 
the uptake of NTBI in hepatocytes under iron-overload conditions.  
Iron recycling: Macrophages are responsible for recycling iron. They digest aged red blood 
cells and release hemoglobin (Hb), which in turn releases heme. HO1 removes iron from 
heme, which can then be stored in ferritin or exported to the blood to support erythropoiesis 
via FPN. Ceruloplasmin oxidizes Fe2+ to Fe3+ in order for iron to be loaded into transferrin. 
Adapted from Darshan et al, 2010.  
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 Most iron inside the cell is used for heme and Fe-S cluster biogenesis in the 
mitochondria (reviewed in [21, 22]). Iron is imported into the mitochondria via the 
inner membrane protein mitoferrin (Mfrn) 1 [23] or 2 [24], in erythroid and non-
erythroid cells respectively. The mitochondrial inner membrane ATP-binding cassette 
transporter ABCB10 enhances the stability of Mfrn1 and, as a consequence, the iron 
flux to the mitochondria increases [25]. The synthesis of heme and Fe-S clusters are 
coordinately regulated by iron availability (reviewed in [26]). The ABC7 
mitochondrial transporter is implicated in the export of Fe-S clusters from the 
mitochondria to the cytoplasm [27]. Studies on the human frataxin homologue in 
yeast show that it is required for mitochondrial iron export [28] and storage [29]. A 
mechanism for heme export from the mitochondria is not yet known.  
 Consistent with their role in transporting oxygen in the body, red blood cells 
need a large amount of iron. To cope with the high demand of iron for erythropoiesis 
and knowing that only a small percentage of iron is taken up daily from the diet, 
macrophages have an imperative role in recycling iron from aging erythrocytes 
(reviewed in [30]). Macrophages engulf and lyse the senescent erythrocytes so that 
heme iron is released [31]. The compartment where iron is released from heme is still 
not completely determined. Two hypotheses have been suggested where either a) in 
the phagolysosome HO1 releases iron from heme which is then exported to the 
cytosol both by DMT1 and Nramp1 (similar to DMT1 but specifically expressed in 
macrophages) [32], or b) that heme catabolism may occur in the cytoplasm by the 
action of HO1 with heme being exported from the phagolysosome via the heme 
transporter HRG1 [33]. Despite different possible routes for heme catabolism, iron is 
either stored in ferritin or exported by FPN to support erythropoiesis. Ceruloplasmin 
oxidizes Fe2+ to Fe3+ for loading onto transferrin (Figure 1.1). 
 Hepatocytes are known for storing a large amount of iron and providing it 
when needed [34]. Apart from TfR1, hepatocytes also express TfR2 (homologue to 
TfR1). In contrast to TfR1, TfR2 does not substantially contribute to the iron-uptake 
and contributes more to regulating iron homeostasis [35], an aspect that will be 
covered in detail in the Section 1.1.4. When the saturation of transferrin exceeds 60%, 
its capacity to bind to iron is reduced and leads to increased “free” iron, or non-
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transferrin bound iron (NTBI) (reviewed in [22]). The ZRT/IRT-like protein 14 
(ZIP14) is increased upon increased levels of iron and it is described to mediate the 
uptake of NTBI in the liver thus contributing to the high amount of iron taken up by 
this organ [36, 37].  The prion-protein (PRNP) is a partner of ZIP14 and reduces 
NTBI to Fe2+ by its ferrireductase activity thus mediating its transport to hepatocytes 
[38] (Figure 1.1). 
 
1.1.3 Cellular Iron Homeostasis 
 Organisms require iron for their vital processes, however an excess of iron is 
also toxic at the cellular level and therefore cells must regulate iron uptake and 
release. Cellular iron homeostasis is achieved by the iron-responsive element/iron 
regulatory protein (IRE/IRP) network (Figure 1.2). This system controls mRNA 
stability or translation of genes important for the uptake, storage and export of iron 
(iron-related genes) in a coordinated fashion (reviewed in [22]). IREs are 
characterized by hairpin structures present at untranslated regions (UTR) of mRNA 
from iron-related genes. Two cytosolic IRPs have been identified to bind to IREs. 
IRP1 is a bifunctional protein, it can either function as an iron regulatory protein or 
acquire an Fe-S cluster and function as an cytosolic aconitase, an enzyme involved in 
citrate metabolism [39]. IRP2 is a homologue to IRP1 but lacks the aconitase activity 
[40].  
 When cells are iron-depleted, the IRPs serve as RNA-binding proteins and 
bind to IREs at the 5’UTR of the heavy (H) and light (L) chain of ferritin [41] and 
FPN [15] mRNAs, thus inhibiting their translation [42]. As a consequence, iron is not 
stored in ferritin and remains inside the cell in order to be utilized. In the same 
conditions, IRPs bind to the 3’UTR of TfR1 and DMT1 mRNAs protecting them 
from degradation ([43, 44] and reviewed in [45]). The stabilization of the TfR1 and 
DMT1 mRNAs leads to the increase in both systemic and dietary iron uptake. 
Conversely, in iron-rich cells the activity of the IRPs is inhibited. IRP1 acquires an 
Fe-S cluster and dissociates from target mRNAs [46, 47], whereas IRP2 is degraded 
by the proteasome [48]. The inactivation or degradation of the IRPs allows the mRNA 
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of TfR1 and DMT1 to be degraded, decreasing iron uptake, and ferritin and FPN to be 
translated, stimulating iron storage and export from the cell.  
 
                
Figure 1.2: Cellular iron regulation. 
In iron-deficient cells, the binding of IRPs to the 5’UTR of the mRNAs for ferritin L and H-
chain and FPN prevents their translation thus preventing iron from exiting the cell and 
potentiating the iron release from the stores. IRPs stabilize the mRNA of TfR1 and DMT1, 
which leads to an increase in iron uptake. In iron-rich cells, IRP1 acquires an Fe-S cluster 
and loses its ability to bind to IREs whereas IRP2 is degraded in the proteasome. This 
inactivation of the IRPs leads to the increase in FPN and ferritin L and H-chain mRNA, thus 
stimulating iron export and sequestration of iron in ferritin. mRNA of TfR1 and DMT1 are 
degraded shutting down iron uptake from the blood and diet respectively. Adapted from 
Hentze et al, 2004. 
 
 
 
 
1.1.4 Systemic Iron Homeostasis 
 It is of great importance that dietary iron uptake from duodenal enterocytes, 
storage and release of iron by hepatocytes, and the recycling of iron from aged 
  Introduction 
 
7 
erythrocytes by macrophages are regulated. Systemic iron homeostasis is achieved by 
the production of a hepatic hormone which controls iron fluxes - the peptide hormone 
hepcidin (mouse - Hamp1, human - Hepc).   
 
Discovery and function of hepcidin 
 Hepcidin was first discovered after being isolated from human urine and blood 
samples as a defensin-like peptide with antimicrobial activity against several 
pathogens [49, 50]. Hepcidin was found to be synthetized mostly by the liver as an 84 
amino acid long pre-pro-peptide. However, only the post-translationally processed 20 
and 25 amino acid forms were prevalent in the urine [50]. Although the first entry of 
hepcidin in UniProt (Universal Protein Resource) dates December 1998 
(http://www.uniprot.org/uniprot/P81172), it was only in 2001 when it was suggested 
that hepcidin could have a role in iron homeostasis. Early work describes that the 
mRNA of hepcidin was increased in the liver of mice fed with a high-iron diet or 
iron-dextran injected mice [51]. It was also shown that disruption of the hepcidin gene 
leads to an iron-overload phenotype in mice [52]. Work throughout the years has 
elucidated in more detail the role of hepcidin in systemic iron control. 
 Hepcidin is produced by hepatocytes in response to increased iron levels. The 
convertase furin cleaves the immature 84 amino acid protein into an active 25 amino 
acid form before it is secreted by hepatocytes [53]. In the blood, hepcidin associates 
with α-2-macroglobulin, which promotes its efficient targeting to cells [54]. It acts by 
binding to an extracellular loop of FPN expressed in hepatocytes, macrophages and 
enterocytes [55]. The interaction between hepcidin and ferroportin triggers the 
ubiquitination of ferroportin. This post-translational modification directs FPN for 
internalization by endocytosis and its degradation in the lysosome [55, 56]. Thus, the 
hepcidin-ferroportin axis is crucial for systemic iron homeostatic control. High 
systemic iron levels induce hepcidin expression, which in turn decreases iron export 
from cells by degrading ferroportin. In iron deficiency, hepcidin expression is reduced 
so that iron can be released from cells via FPN (Figure 1.3). 
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Figure 1.3: Systemic iron regulation.  
Hepatocytes activate the expression of hepcidin in response to high iron levels. Hepcidin is 
secreted to the serum where it binds to the ferroportin present at the membrane of 
hepatocytes, duodenal enterocytes and macrophages. The binding of hepcidin to ferroportin 
triggers its degradation leading to the reduction of iron export. Conversely, hepcidin 
expression is reduced under iron depletion so that ferroportin remains stable at the cell 
membrane and iron is exported to the serum.  
 
 
Regulation of Hepcidin 
 Hepcidin is the master regulator of systemic iron homeostasis, and therefore 
hepcidin must be tightly controlled. To date, the only known mechanism for hepcidin 
control is the regulation of its mRNA expression. The hepcidin promoter responds to 
a variety of different signals. Three major stimuli for the hepcidin regulation are the 
iron status, inflammation and erythropoietic signals, although increasing evidence has 
shown that the hepcidin transcriptional regulation extends beyond these three core 
regulatory processes (Figure 1.4).  
 
  Introduction 
 
9 
        
 
Figure 1.4: Regulation of hepcidin transcription.  
In high iron conditions, BMP6 binds to BMPR-I and BMPR-II triggering the 
phosphorylation of the transcription factors SMAD1/5/8. p-SMAD1/5/8 associates with the 
co-activator SMAD4 and is translocated into the nucleus. This complex binds to the BMPREs 
present at the promoter of hepcidin, activating its transcription. The complex of TfR1, TfR2 
and HFE sense iron levels and cross-talk to the BMP pathway to up-regulate hepcidin 
transcription. In inflammatory conditions, IL6 binds to its receptor triggering the 
phosphorylation of the STAT3 transcription factor. p-STAT3 is transported to the nucleus and 
binds to the STAT-BS present at the promoter of hepcidin. The binding of STAT3 to the 
STAT-BS induces hepcidin transcription. Both gluconeogenesis and ER stress induce 
hepcidin expression by activating the CREBH transcription factor. EPO stimulates 
erythropoiesis during hypoxia. In these conditions, hepcidin suppressors such as TWSG1 
and ERFE are produced and act on the liver to negatively regulate hepcidin transcription.  In 
addition, PDGF-BB binds to the PDGF receptor, preventing CREBH from activating 
hepcidin. The growth factor EGF, the hormone testosterone and proliferative stimuli due to 
growth and nutrient signals, suppress hepcidin expression. Adapted from Rishi et al, 2015. 
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Hepcidin regulation by the iron status 
 The signaling pathway which responds to iron levels and is involved in 
modulating hepcidin expression in the liver is the bone morphogenic protein (BMP)-
sma and mother against decapentaplegic (SMAD) pathway. BMPs are secreted 
cytokines which belong to the transforming growth factor-β (TGF-β) family and are 
involved in regulating many basic cellular processes (reviewed in [57]). In response to 
increasing systemic iron levels, non-parenchymal cells (NPCs) of the liver produce 
and secrete BMP6 [58], the predominant BMP involved in hepcidin regulation [59]. 
The mechanism by which NPCs sense iron and activate BMP6 transcription is yet to 
be elucidated. Although hepatocytes also have detectable levels of Bmp6 mRNA and 
therefore could control hepcidin expression in a paracrine manner, it is believed that 
the BMP6 produced by the NPC is the major contributor to the BMP6-induced 
hepcidin expression in hepatocytes [58]. Secreted BMP6 binds to the BMP receptors 
at the cell membrane of hepatocytes. Functional BMP receptors are composed of two 
type I and two type II subunits. The relevant receptors for iron homeostasis are the 
activin receptor-like kinase 2 (ALK2) and BMP receptor 1a (BMPR-1A/ALK3) (type 
I receptors), and the BMPR-II and activin type II receptor (ActR-II) [60-62]. The 
binding of BMP6 to these type I receptors triggers the activation of a serine-threonine 
kinase located in the type II receptors, which in turn recruits and phosphorylates the 
SMAD1, SMAD5 and SMAD8 transcription factors (SMAD1/5/8) [57, 63]. 
Phosphorylated SMAD1/5/8 (p-SMAD1/5/8) then associates with the co-activator 
SMAD4. This complex is translocated into the nucleus where it binds to the promoter 
of hepcidin thus activating its transcription. The expression of SMAD7 is induced by 
BMP6 and it acts as a suppressor in a negative feedback loop for the suppression of 
hepcidin transcription [64]. There are two conserved BMP responsive elements 
(BMPRE) in the human hepcidin promoter. These BMPREs are located at different 
positions, with the BMPRE1 being proximal (-84/-79) and the BMPRE2 being distal 
(-2255/-2250) (Figure 1.4). Mutations in these regions strongly reduce hepcidin 
expression, showing that these motifs are crucial for the regulation of hepcidin [65]. 
In the mouse promoter, one BMPRE has been identified at the position -200/-140 
[66].  
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 Other molecules interact with the BMP/SMAD pathway and contribute to the 
iron-induced hepcidin regulation. The membrane protein hemojuvelin (HJV) is a 
BMP co-receptor necessary for the stimulation of hepcidin transcription [67]. The 
matriptase-2 (TMPRSS6) exerts an inhibitory effect on the BMP pathway by cleaving 
the HJV into a soluble form [68]. The cleaved HJV then competes with BMP6 for the 
binding to its receptor resulting in a reduction of the p-SMAD1/5/8 and hepcidin 
expression.  
 The communication between iron levels and the expression of the hepcidin 
gene is not only accomplished by means of BMP6 stimulation. TfR1, TfR2 and the 
membrane protein HFE in hepatocytes sense circulating iron levels through iron 
bound-transferrin. Upon binding of iron-loaded transferrin, HFE is displaced from 
TfR1. The dissociation of HFE from TfR1 not only increases the affinity of this 
receptor to transferrin but also triggers hepcidin expression [69, 70]. It has been 
suggested that HFE, TfR2 and HJV form a complex, which could be important for the 
regulation of hepcidin [71, 72]. Contrary to this, it was suggested that these proteins 
do not need to interact to modulate hepcidin [73, 74]. Therefore, further investigation 
must be carried out in order to clarify the involvement of this complex in regulating 
hepcidin levels. Despite the unclear role of HFE/TfR2/HJV in the control of hepcidin 
as a complex, it is well documented that HFE stabilizes BMPR1A leading to the up-
regulation of hepcidin transcription [75]. Furthermore, Hfe- and Tfr2-null mice 
present diminished p-SMAD1/5/8 reflecting the importance of these proteins for the 
regulation of hepcidin via the BMP/SMAD signaling pathway [76] (Figure 1.4). 
 
Hepcidin regulation by inflammatory stimuli 
 Pathogen growth depends upon iron availability. Therefore, upon 
inflammation, the transcription of hepcidin is up-regulated in order to limit the iron 
level in the blood [51]. In response to inflammatory stimuli, the circulating cytokine 
interleukin 6 (IL6) increases hepcidin levels via the janus kinase (JAK)-signal 
transducer and activator of transcription 3 (STAT3) signaling pathway [77, 78]. The 
binding of IL6 to its receptor activates the JAK kinase resulting in the 
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phosphorylation of the STAT3 transcription factor (reviewed in [79]). The 
phosphorylated form of STAT3 is then transported to the nucleus where it binds to the 
promoter of hepcidin at a region known as the STAT-binding site (position -72/-64 in 
the human promoter) [80] (Figure 1.4).   
 Studies have uncovered an intertwined network involving the BMP/SMAD 
and the JAK/STAT pathways. Hepatocytes lacking Smad4 in the liver [81] or mice 
administered with a BMPR1A inhibitor [82] do not efficiently up-regulate hepcidin 
when challenged with IL6. In addition, mice treated with lipopolysaccharide (which 
triggers inflammation) show increased p-SMAD1/5/8 compared to control mice and it 
is believed that this response involves the binding of the cytokine activin B to BMP 
receptors [83].  
 
Hepcidin regulation by erythropoietic signals 
 Iron is an element present in hemoglobin, which is essential for red blood cells 
to carry out their function as oxygen transporting cells. Thus, increased erythropoiesis 
requires a supply of iron. For this reason, hepcidin has to be regulated according to 
the erythropoietic demand. This process involves communication between different 
organs in a coordinated manner. Erythropoietin (EPO) is a cytokine synthesized by 
the kidneys in hypoxic conditions, which controls erythropoiesis in the spleen and 
bone-marrow (reviewed in [84]). As a result, a stimulation of the recently identified 
secretory protein erythroferrone (ERFE) occurs, which in turn acts directly on the 
liver to suppress hepcidin [85] (Figure 1.4). The suppression of hepcidin leads to an 
increase in iron availability in the serum, which is used for erythropoiesis. Little is 
known about the mechanism by which erythroferrone suppresses the transcription of 
hepcidin. So far, one initial study shows that the suppression of hepcidin does not 
involve the BMP/SMAD pathway [85] whereas more recent work suggests that the 
hepcidin inhibitor TMPRSS6 is necessary to attenuate the activity of the BMP/SMAD 
pathway in response to ERFE [86]. 
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 Apart from ERFE, two other molecules are described to play a role in hepdicin 
down-regulation upon high erythropoietic demand. Erythroblasts, precursors of red 
blood cells, produce both the twisted gastrulation BMP signaling modulator 1 
(TWSG1) and the growth differentiation factor 15 (GDF15). While it is known that 
TWSG1 suppresses the expression of hepcidin by reducing the activity of the 
BMP/SMAD pathway in hepatic cells [87], whether GDF15 has a role in suppressing 
hepcidin expression is controversial [88, 89] (Figure 1.4).  
 In addition to EPO stimulation, low oxygen levels induce the expression of the 
platelet-derived growth factor (PDGF)-BB. The PDGF-BB factor has been described 
as a repressor of hepcidin under hypoxic conditions. The PDGF-BB-mediated 
suppression of hepcidin is achieved by the binding of PDGF-BB to PDGF receptors, 
which inactivate the CREBH transcription factor [90] (Figure 1.4).  
 
Other regulators of hepcidin 
 In addition to the three major stimuli that regulate hepcidin (iron status, 
inflammation and erythropoietic signals), hepcidin modulation has been linked to sex 
hormones, proliferation and growth factors as well as to metabolism. Testosterone is 
reported to repress hepcidin by acting on the epidermal growth factor receptor 
(EGFR) of hepatocytes [91] (Figure 1.4). Contradicting work has shown hepcidin 
being both up- or down-regulated in response to increased estrogen levels [92, 93]. 
Several proliferative stimuli have been reported to suppress hepcidin expression. It 
has been demonstrated that growth factors involved in tissue formation such as the 
hepatocyte growth factor (HGF) and epidermal growth factor (EGF) suppress 
hepcidin mRNA (Figure 1.4), possibly by blocking the translocation of p-SMAD1/5/8 
to the nucleus in hepatocytes [94]. Consistently, it has been shown that growth signals 
involving the rapidly accelerated fibrosarcoma (Ras-RAF) mitogen-activated protein 
kinase (MAPK) signaling pathway, target of HGF and EGF, repress hepcidin 
transcription [95] (Figure 1.4). Proliferative signals involving the nutrient-dependent 
mammalian target of rapamycin (mTOR) signaling pathway have also been linked to 
the repression of hepcidin [95] (Figure 1.4). Furthermore, gluconeogenic signals 
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increase hepcidin levels through the activation and cooperative binding of CREBH 
and the peroxisome proliferator and activated receptor gamma coactivator 1-α (PGC-
1α) to the promoter of hepcidin [96] (Figure 1.4).   
 
 
1.1.5 Iron-Related Diseases  
 Perturbation of systemic iron homeostasis is associated with disease. The 
common cause for most of the iron-related disorders is the dysregulation of the 
hepcidin-ferroportin axis. Iron-related diseases are divided into an iron-overload or 
iron-deficiency disorders, depending on whether iron is in excess or depleted in the 
body.  
 
Iron-overload disorders 
 Accumulation of iron in the body leads to hereditary hemochromatosis (HH), 
which is characterized by high oxidative stress and organ failure. HH is a genetically 
heterogenous autosomal recessive disorder, divided into four types according to its 
severity (reviewed in [97, 98]) (Table 1.1). The HH type I is typically a relatively 
mild and late onset form and it is the most frequent type of HH, more than 80% of all 
HH cases. It is characterized by mutations in the Hfe gene [99] leading to an inability 
of HFE to be expressed on the cell surface [100]. It has been described that the 
mutated HFE protein fails to prevent ALK3 receptor's ubiquitination and proteasomal 
degradation [75]. Therefore, it may be the cause of inappropriately low hepcidin 
levels in patients with HH type I [101, 102]. HH type II is a more severe type of HH. 
Patients present first symptoms of iron overload during childhood (juvenile HH). HH 
type II is characterized by mutations either in the Hjv gene (type II-a) [103] or in the 
hepcidin gene (type II-b) [104]. Both cases of HH type II are associated with 
extremely low hepcidin levels. The HH type III is a rare form of HH. This type of HH 
is similar to HH type I in terms of disease progression however the mutation is 
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present in the Tfr2 gene [105]. Similarly to other types of HH, a mutation in this gene 
impairs the capacity of liver cells to sense iron levels and results in low hepcidin 
expression. The genetics of the HH type IV differs from other types of HH. The HH 
type IV is autosomal dominant. Contrasting to other types of HH, which affect the 
expression of hepcidin, HH type IV is associated with mutations in the ferroportin 
gene [14]. Two different types of mutations have been identified, which lead to 
different phenotypes. One type results in a gain of function of ferroportin causing 
resistance to hepcidin [106]. As a consequence, iron is continuously exported from 
the iron-releasing cells hence generating iron overload in the serum [107]. The second 
type of mutation results in the loss of the ferroportin function [108]. The lack of a 
functional ferroportin leads to iron retention and accumulation in ferroportin-
expressing cells but decreased iron in the serum.   
 Patients with HH can be treated by regular phlebotomy (blood withdrawal) in 
order to remove the iron-rich red blood cells. In the ferroportin disease, iron chelation 
can be an alternative treatment (reviewed in [97]). 
 
Table 1.1: Hereditary Hemochromatosis types. 
 
Iron-deficiency disorders 
 Iron-deficiency can be caused by continuous blood loss or inadequate dietary 
iron absorption (reviewed in [109]). Genetically, low serum iron can be due to 
mutations in the Tmprss6 gene. These mutations cause inappropriately high levels of 
hepcidin, preventing iron from being absorbed from the diet or released from stores. 
This phenotype leads to the iron-refractory iron deficiency anemia (IRIDA) [110]. 
Hereditary 
Hemochromatosis Mutated Gene Pattern of Inheritance 
Age of 
Symptoms Onset 
Type I Hfe Autosomal recessive 30-40 years-old 
Type II-a Hjv Autosomal recessive 10-20 years-old 
Type II-b Hepc Autosomal recessive 10-20 years-old 
Type III Tfr2 Autosomal recessive 30-40 years-old 
Type IV Fpn Autosomal dominant 30-40 years-old 
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Iron-deficiency can also occur as a consequence of persistent intestinal bleeding. 
Furthermore, disorders such as chronic inflammation or chronic liver and kidney 
diseases highly increase hepcidin expression, leading to a particular iron-deficiency 
type designated anemia of inflammation (AI) or anemia chronic diseases (ACD) 
[111]. There is no specific treatment for IRIDA or AI/ACD. Erythropoietic 
stimulators and supplementation of iron intravenously in patients are usually not 
effective. Thus, the control of hepcidin expression by pharmacological drugs holds a 
more promising avenue. Among these hepcidin antagonists are inhibitors targeting the 
BMP/SMAD and JAK/STAT pathways. Injections with soluble HJV have shown to 
efficiently down-regulate hepcidin levels. Although the preclinical results are 
encouraging, all these options are still being tested only in animal models. More 
advanced studies involve the production of humanized anti-hepcidin antibodies or 
antibodies against the hepcidin binding site on ferroportin and are currently under 
phase I of clinical trials (reviewed in [112]). 
 
1.2  Cellular Metabolism 
1.2.1 Overview of Metabolism 
  Metabolism is a life-sustaining process divided into two phases: i) catabolism 
is the energy (adenosine triphosphate (ATP))-producing process in which 
carbohydrates, fats and proteins are degraded to precursor molecules, and ii) 
anabolism is an ATP-consuming process in which precursor molecules are used to 
build up complex macromolecules. In order for cells to achieve a metabolic balance, 
they have to coordinate energy production and expenditure. These processes can be 
regulated in various ways. Enzymatic activities can be modulated by the availability 
of their substrates, by allosteric binding of small molecules that signal the metabolic 
state of the cell (such as ATP, citrate), or by the coordination of the metabolic activity 
between different tissues, which involve the production of growth factors and 
hormones (reviewed in [113]).   
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 The citric acid cycle (also called the tricarboxylic acid (TCA) cycle or Krebs' 
cycle) occurs in the mitochondria and is central to energy metabolism. It accounts for 
the degradation of carbohydrates, fats and proteins to generate ATP while it also 
functions as a biosynthetic pathway to produce glucose, fatty acids and non-essential 
amino acids.  
 
1.2.2 Citrate Metabolism 
 Citrate (citric acid) is an intermediate of the citric acid cycle that is generated 
as a result of the reaction of acetyl-coA with oxaloacetate, which is catalyzed by the 
citrate synthase (CS) enzyme in the mitochondria. The oxidation of citrate within the 
citric acid cycle accounts for the major source of cellular ATP production. The 
generation of citrate stimulates the flow of the cycle, which leads to the generation of 
reduced nicotinamide adenine dinucleotide (NADH), reduced flavin adenine 
dinucleotide (FADH2) and succinate. These molecules are crucial for ATP production 
by the electron transport chain (ETC) and oxidative phosphorylation. Hence, the 
production of citrate correlates with the production of ATP, which means that high 
levels of citrate indicate that ATP levels are elevated (reviewed in [114, 115]). Under 
this condition, citrate adjusts the activity of the citric acid cycle enzymes, as well as 
the breakdown of glucose (glycolysis), to meet the cellular need for ATP (Figure 1.5).  
 High citrate levels slow-down the citric acid cycle by directly repressing the 
activity of the pyruvate dehydrogenase (the enzyme that generates acetyl-coA from 
pyruvate) (PDH) [116], and both the citric acid cycle enzymes citrate synthase (rate-
limiting) [117] and succinate dehydrogenase (SDH) [118]. As a consequence of its 
accumulation in the mitochondria, citrate can also be transported to the cytoplasm. 
There, it regulates important key enzymes for glycolysis, gluconeogenesis and fatty 
acid synthesis. Citrate allosterically inhibits the activity of phosphofructokinase-1 
(PFK1), the rate-limiting enzyme in glycolysis, which converts fructose 6-phosphate 
into fructose 1,6-bisphosphate (F1,6P) (reviewed in [119]). F1,6P is an activator of 
the pyruvate kinase (PK), which generates pyruvate. Therefore, by decreasing the 
levels of F1,6P, citrate indirectly reduces the activity of PK (reviewed in [120]). The 
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inhibition of PFK1 and PK activities leads to the reduction in pyruvate and acetyl-coA 
levels, resulting in reduced production of ATP. Apart from regulating glycolysis, 
citrate is also able to regulate the gluconeogenic process by inducing the activity of 
the fructose 1,6-biphosphatase (F1,6BPase). Therefore, citrate has a dual role in 
regulating glucose metabolism in the cytoplasm. It represses glycolysis and energy 
production whilst it can stimulate gluconeogenesis (reviewed in [119]).  
 High levels of citrate in the cytoplasm also stimulate fatty acid biosynthesis. 
Citrate is metabolized to oxaloacetate and acetyl-coA by the ATP citrate lyase 
(ACLY) enzyme. While oxaloacetate is converted to pyruvate and enters a new round 
of oxidation in the citric acid cycle, the acetyl-coA serves as a precursor for fatty acid 
synthesis (reviewed in [114]).  
 Another layer of complexity for citrate-dependent regulatory mechanisms 
emerges from the ability of citrate to regulate transcription. The regulation of gene 
expression is achieved by histone modifications, such as acetylation. Histone 
deacetylases and acetyltransferases target specific regions in the genome exposing or 
constraining promoters to the binding of transcription factors (reviewed in [121]). The 
activity of histone acetyltransferases (HATs) is limited by acetyl-coA levels. ACLY is 
found in the nucleus where it converts citrate to acetyl-coA, serving as a substrate for 
acetylation reactions. Among genes regulated by ACLY activity are genes encoding 
glycolytic enzymes, such as glucose transporter type 4 (GLUT4), hexokinase-2 
(HXK2), PFK1 and lactate dehydrogenase A (LDHA) ([122]). Hence, citrate is 
postulated to control glycolysis directly by modulating the enzymatic activity of some 
of the enzymes involved in this pathway as well as by controlling their gene 
expression.  
 Other enzymes apart from citrate synthase and ACLY are involved in citrate 
metabolism. The mitochondrial aconitase (ACO2) acts in the citric acid cycle and 
converts citrate into iso-citrate in the mitochondria whereas the cytosolic aconitase 
(ACO1) is the functional homologue of ACO2 in the cytoplasm (reviewed in [123]). 
ACO1 can also act as an iron-binding protein depending upon the iron availability in 
the cell (previously described in Section 1.1.3). Citrate metabolism is summarized in 
Figure 1.5. 
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Figure 1.5: Citrate metabolism. 
Glycolyis is stimulated in response to abundant glucose. As a consequence, pyruvate is 
synthesized in the cytoplasm and transported to the mitochondria where it is converted to 
acetyl-coA, which enters the citric acid cycle. Citrate is an intermediate synthesized in the 
citric acid cycle as a result of the condensation of oxaloacetate with acetyl-coA catalyzed by 
the CS enzyme. The enzyme ACO2 is the second enzyme of the citric acid cycle and converts 
citrate into iso-citrate. High flux through the citric acid cycle leads to the generation of ATP. 
Therefore, citrate and ATP levels correlate. When the cellular demand for ATP is fulfilled, 
citrate accumulates in the mitochondria and represses the enzymatic activity of PDH, CS and 
SDH thus reducing the flow of the cycle and ATP production. At the same time, citrate is 
transported to the cytosol where it inhibits the activity of the glycolytic enzymes PFK1 and 
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PK. This repression results in the attenuation of glycolysis and the supply of acetyl-coA to the 
citric acid cycle. Citrate can stimulate F1,6BPase and thus promotes gluconeogenesis. Citrate 
can be metabolized to iso-citrate by ACO1 or to acetyl-coA and oxaloacetate by ACLY in the 
cytoplasm. The acetyl-coA formed in the cytosol promotes lipogenesis. Citrate and the ACLY 
enzyme can also be found in the nucleus where they promote acetylation of histones and 
activate the transcription of genes involved in glycolysis, such as HXK, GLUT4 and LDHA. 
Adapted from Icard et al, 2012. 
 
  
1.3 Iron and Metabolism 
 Increasing evidence suggests that the mechanisms involved in controlling iron 
homeostasis may influence metabolic processes. A single IRE sequence was 
identified in the 3'UTR of the glycolate oxidase mRNA (involved in ROS 
detoxification) by analysis of total poly(A)+ mRNA precipitated bound to 
recombinant  IRP1 [124]. By computational analysis of the consensus sequence of 
IREs, IREs were identified in the 5'UTR of mRNA coding for enzymes such as δ-
aminolevulinate synthase 2 (heme biosynthesis) [125], mitochondrial aconitase (citric 
acid cycle) and succinate dehydrogenase (citric acid cycle) [126]. Furthermore, cancer 
cells treated with iron show increased activity of citric acid cycle enzymes such as 
mitochondrial aconitase, citrate synthase and iso-citrate and succinate dehydrogenases 
compared to untreated cells [127]. Conversely, cells treated with desferrioxamine (an 
iron chelator) show reduced enzymatic activities of the same enzymes. Therefore iron 
availability has an impact on the citric acid cycle activity, which in turn impacts on 
energy production [127]. Consistent with this, others have shown that rats fed with an 
iron deficient diet show reduced activities of the cytochrome c, cytochrome c oxidase 
I and succinase dehydrogenase enzymes (crucial for the electron transport chain - 
energy production) in skeletal muscle cells [128]. 
 In turn, several studies have shown that metabolic changes are able to regulate 
iron homeostasis. Epinephrine and norepinephrine are hormones that increase the rate 
of energy metabolism. Treatment of hepatocytes, skeletal muscle cells and mice with 
epinephrine/norepinephrine stimulates the binding of IRP1 to IRE sequences located 
in TfR1 and ferritin mRNAs. This leads to the stabilization of the TfR1 transcript, and 
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increased transferrin bound iron uptake. In addition, ferritin translation is inhibited, 
which causes reduced iron storage. The resulting increase in iron availability supports 
the activity of iron-dependent proteins, which are involved in the citric acid cycle and 
electron transport chain [129].  
 Iron metabolism and hepcidin transcriptional control have been linked to the 
nutrient-sensing mTOR pathway. The mTOR pathway regulates crucial metabolic 
processes such as cell size, proliferation, survival and lipid synthesis (reviewed in 
[130]). A siRNA screen of the human signaling proteome in HeLa cells identified 
members of the mTOR signaling pathway which control transferrin uptake. siRNA-
mediated knockdown of tuberous sclerosis complex 2 and phosphatase and tensin 
homolog (known mTOR suppressors) enhances transferrin uptake whereas 
knockdown of pyruvate dehydrogenase kinase 1, RAC-alpha serine/threonine-protein 
kinase and mTOR (known activators) suppresses transferrin uptake [131]. 
Furthermore, it has been described that incubation of mouse preadipocytes and lung 
fibroblasts with rapamycin (inhibitor of the mTOR signaling pathway) induces the 
phosphorylation of the iron-sulfur cluster assembly enzyme (ISCU). The stabilization 
of the ISCU protein results in an increase in its abundance in the mitochondria thus 
potentiating the assembly of Fe-S clusters [132]. Moreover, siRNA-mediated 
knockdown of activators of the mTOR signaling pathway increase hepcidin gene 
expression. Consistently, treatment of primary hepatocytes and hepatocytic cell lines 
with rapamycin lead to the activation of hepcidin transcription [95]. Work in mice has 
shown that mice in starvation, a condition in which gluconeogenesis is stimulated due 
to the lack of glucose intake, show increased levels of hepcidin compared to control 
mice [96], suggesting that gluconeogenic stimuli regulate hepcidin expression. 
 Iron perturbations have also been associated with metabolism-related diseases. 
Hepcidin mRNA levels are increased in patients with obesity [133]. Patients with 
metabolic syndrome show increased levels of hepcidin in the blood [134]. In turn, 
patients with diabetes mellitus show altered hepcidin levels, which can be either 
increased or decreased, depending upon the inflammatory status of the patient ([135-
137]. 
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1.4 Aim of the Study 
 Links between hepcidin regulation and alterations in metabolism have been 
identified. However, the underlying mechanisms are poorly understood. In my thesis 
project I set out to characterize links between cellular metabolism and hepcidin 
expression.  
 I took advantage of data obtained from a genome-wide small interfering-RNA 
(siRNA) screen previously performed in our laboratory [95], which aimed to identify 
candidates for transcriptional regulators of hepcidin. This screen was performed by 
co-transfecting the hepato-cellular carcinoma cell line HuH7 with a reporter plasmid, 
containing the luciferase gene under control of the human full-length hepcidin 
promoter, and siRNAs targeting the near complete set of human protein-coding genes. 
Data obtained from this screen (about 1500 activators and 500 repressors) were 
analyzed by the DAVID tool to identify genes involved in metabolic reactions [95].  
 My specific aims were to: 
 I. Select putative hepcidin regulators identified in the RNAi screen, which are 
 involved in metabolism. 
 II. Validate the putative regulators of hepcidin in primary mouse 
 hepatocytes. 
 III. Perturb metabolic pathways associated with the validated effectors and   
 investigate their role in hepcidin expression. 
 IV. Validate the data in mice in vivo and assess the physiological 
 consequences of the manipulation of these effectors for hepcidin regulation.
   
 
 
 
 
 
 
 
 
 
 
Chapter 2  
Experimental Procedures 
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2 Experimental Procedures 
2.1 Frequently used reagents, chemicals and 
materials 
   
 Glycine, Tris-(hydroxymethyl)-methylamine (Tris), sodium chloride (NaCl), 
methanol, ethanol, isopropanol and sodium dodecyl sulphate (SDS), 
deoxyribonucleotides triphosphate (dNTPs), chloride acid (HCl), sodium bicarbonate 
(NaHCO3) and Tween® were bought from Carl Roth GMBH. Citric acid (suitable for 
cell culture), fumaric acid (suitable for cell culture), succinic acid (suitable for cell 
culture), α-ketoglutaric acid disodium salt monohydrate, potassium citramalate 
monohydrate, Dulbecco’s phosphate buffered saline (PBS), trypan-blue, 
dexamethasone, insulin from bovine pancreas, ethylenediaminetetraacetic acid 
(EDTA), NP40, glycerol, β-merceptoethanol, bromophenol blue, Triton X-100, 
Empigen BB, lithium chloride (LiCl) and sodium deoxycholate were obtained from 
Sigma-Aldrich. Opti-MEM®, fetal bovine serum (FBS), sodium pyruvate, liver 
perfusion medium and liver digest medium were obtained from Gibco. Williams' 
medium E and penicillin/streptomycin were purchased from Biochrom. Percoll and 
nitrocellulose membranes were obtained from GE Healthcare. Random primers, 
salmon sperm DNA and GlutaMAX were purchased from Invitrogen. The compound 
BMS-30314 was obtained from Tocris. Lipofectamine RNAiMAX Transfection 
Reagent and RevertAid H Minus Reverse Transcriptase were purchased from Thermo 
Scientific. Protein A/G magnetic beads were obtained from Pierce. Tungsten carbide 
beads (3 mm) were purchased from Qiagen. Cell culture multi-well collagen I-coated 
plates and dishes were obtained from (Corning). Tubes and falcons were obtained 
from Sarstedt or Greiner Bio-One. TRIzol®Reagent was bought from Ambion. 
SYBR-Green was obtained from Applied Biosystems.  
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2.2 Buffers and Solutions 
 
 
Running buffer for SDS-PAGE: 
25 mM Tris  
192 mM Glycine  
0.1% SDS 
 
 
Transfer buffer for Western blot: 
25 mM Tris  
192 mM Glycine  
10% Methanol  
 
 
RIPA buffer for protein extraction: 
10 mM Tris-HCl pH 8.0  
150 mM NaCl  
1 mM EDTA  
1% NP-40  
0,1% SDS  
 
 
Laemli Buffer for protein loading (4x): 
250 mM Tris-HCl pH 6.8  
8% SDS  
40% Glycerol  
10% β-Mercaptoethanol  
0.06% Bromophenol blue 
 
 
TBS-Tween 0.1% for washing of protein membranes: 
100 mM Tris-HCl pH 7.6 
150 mM NaCl 
0.5% TWEEN®20 
 
 
RC buffer: 
250 mM Saccharose 
50 mM KCl 
5 mM MgCl2 
20 mM Tris HCl pH 7.4 
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2.3 Oligonucleotides, small-interfering RNAs and 
antibodies used in this study  
  
 All antibodies, oligonucleotides and small-interfering RNAs (siRNAs) used in 
this study are listed below. All primers were purchased from Sigma-Aldrich.  
 
Table 2.1: List of oligonucleotides used in this study. 
 
 
Table 2.2: List of antibodies used in this study. 
Mouse target gene Forward primer 5'- 3' Reverse primer 5'- 3' 
Acly aagaaggaggggaagctgat tcgcatgtctgggttgttta 
Aco1 gtcgccaccattctttgaa ggcatccactatggacttgg 
Aco2 gttgggggtgagaaagacct gaagcccacaccatacttgg 
Smad1 cccctaccactataagcgagtg aaggctgtgctgaggattgt 
Smad4 acaccaacaagtaacgatgcc gcaaaggtttcactttcccca 
Bmpr1a tggctgtctgtatagttgctatg tgcttgagatactcttacaataa 
Hjv ccaacgctaccaccatcc cccccattgatagaacccatct 
Hfe caccgtctgtgccatcttctt acatagccacccatggttcct  
Bmp4 tgagtacccggagcgtcc ctccagatgttcttcgtgatgg 
Bmp6 atggcaggactggatcattgc ccatcacagtagttggcagcg 
Bmp7 cgagaccttccagatcacagt cagcaagaagaggtccgact 
Bmp9 ggaagctgtgggtagatgacc caagtcggtggggatgat 
Tgfb1 tggagcaacatgtggaactc cagcagccggttaccaag 
Id1 accctgaacggcgagatca tcgtcggctggaacacatg 
Nact tcacaaaagcccaagttcaa ggggtagaacggagttttcc 
Nadc3 tggatctccttcctctatggtg ctgcgtcagctcgtatctttg 
Hamp1 ataccaatgcagaagagaagg aacagataccacactgggaa 
Rpl19 aggcatatgggcatagggaagag ttgaccttcaggtacaggctgtg 
Hamp1_BMPRE gagccacagtgtgacatcac gtctaggagccagtcccagt 
Target protein Dilution Provider 
Vinculin 1:250 Sigma-Aldrich 
SMAD1 1:1000 Cell signaling 
p-SMAD1/5/8 1:1000 Cell signaling 
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Table 2.3: List of siRNAs used in this study. 
 
2.4 Mice  
 Mice used for the isolation of primary hepatocytes were wild type C57BL6/N, 
male and aged between eight- and thirteen-weeks old. Mice used for in vivo studies 
were male C57BL6/J WT aged eight weeks old. C57BL6/N mice were housed in the 
University of Heidelberg animal facility under a constant light-dark cycle and 
maintained on a standard mouse diet with 200 mg of iron/kg of food (D.Rod18.A07, 
Mouse siRNA name Gene symbol/siRNA ID Provider 
FlexiTube siRNA Mm_Smad1_1 Smad1/SI00177072 Qiagen 
AllStars Negative Control siRNA NA/1027280 Qiagen 
Silencer®Select Negative Control 
#2 siRNA NA/4390846 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Bmp4 Bmp4/s63022 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Smad4 Smad4/s201661 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Bmpr1a Bmpr1a/s63041 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Aco1  Aco1/s61844 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Aco1 Aco1/s61842 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Hfe2 Hjv/s87981 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Hfe Hfe/s67488 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Aco2 Aco2/s61847 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Aco2 Aco2/s61845 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Acly Acly/s98225 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Acly Acly/s98226 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Slc13a5 Nact/s108630 Ambion 
Silencer®Select Pre-designed and 
validated siRNA Slc13a3 Nadc3/s100155 Ambion 
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LASvendi) under ad libitum access to food and water. The isolation of hepatocytes 
from mice was approved by the University of Heidelberg. C57BL6/J mice were 
housed in the EMBL animal facility. C57BL6/J were housed under a constant light-
dark cycle and maintained on a standard mouse diet with 200 mg of iron/kg of food 
(Teklad 2018S, Harlan Laboratories) under ad libitum access to food and water. In 
vivo experiments were approved by EMBL and conducted according to the guidelines 
of the EMBL institutional Animal Care and Use Committee. 
 
2.5 Methods 
2.5.1 Isolation of primary murine hepatocytes 
 Hepatocytes were isolated as previously described in literature [138]. Mice 
were euthanized and the full liver was collected. Liver lobes were cut transversely to 
expose the portal vein and placed on top of a warm surface. Liver cells were isolated 
by perfusion of all individual lobes with 100 ml of liver perfusion medium followed 
by 100 ml of liver digest medium at 37°C by using a 24G cannula connected to a 
peristaltic pump with a speed of 8 ml/minute. Cells were then filtered with a 100 µm 
strainer and purified using a 1.06 g/ml diluted in PBS. Cell viability was accessed by 
trypan-blue exclusion and cells were seeded in William's E medium containing 10% 
of heat-inactivated FBS, 1% penicillin/streptomycin, 1% GlutaMAX, 0.1 nM 
dexamethasone and 10 mg/ml insulin into collagen I-coated plates. After 5 hours, the 
medium was replaced by William's E medium with a different supplement according 
to the experiment (see sections below). Experiments were either performed 
immediately or 16 hours after medium change. Hepatocytes were maintained at 37°C 
with 5% of carbon dioxide (CO2). 
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2.5.2 RNAi experiments 
 Five hours after seeding, hepatocytes (250 000 cells in 12-well plate) were 
washed 3 times with PBS and then William's medium E with 10% of heat-inactivated 
FBS and 1% GlutaMAX was added to cells. Transfections of siRNAs were performed 
by adding 12 pmol of commercially available siRNAs (Table 2.3) and 2 ml of 
Lipofectamine RNAiMAX Reagent into cells according to manufacturer’s 
recommendation. The medium was replaced after 24 hours of transfection by 
William's E medium containing 10% of heat-inactivated FBS, 1% 
penicillin/streptomycin and 1% GlutaMAX and cells were collected 72 hours after 
transfection for total RNA extraction. When combined with citrate treatment, the 
medium was changed to William's E medium with 1% penicillin/streptomycin and 
1% GlutaMAX (without FBS) 38 hours after transfection. Cells were incubated with 
this medium for 1 hour and then 5 mM of a citrate solution or water was added for 9 
hours. Hepatocytes were collected then for total RNA extraction.  
 
2.5.3 Treatment of hepatocytes with small molecules 
 Five hours after seeding, hepatocytes were washed 3 times with PBS and 
William's medium E with 10% of heat-inactivated FBS, 1% penicillin/streptomycin 
and 1% GlutaMAX was added to cells. Treatments were conducted after one hour 
period of starvation from FBS in Williams' medium E with 1% 
penicillin/streptomycin and 1% GlutaMAX (approximately 16 hours after cell 
washing and medium replacement).  
 Potassium citramalate monohydrate (or water) and BMS-30314 (or DMSO) 
were added to the culture medium at a final concentration of 3 mM and 50 µM 
respectively. Hepatocytes were collected 3 hours after treatment with citramalate and 
90 min after treatment with BMS-30314 for total RNA extraction (250 000 cells in 
12-well plate) or measurements of enzymatic activities (750 000 cells in 6-well plate). 
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 Water or citric acid (citrate) were added to the cell culture medium at a final 
concentration of 1 mM and 3 mM. Hepatocytes were collected 3 hours, 6 hours and 9 
hours after treatment for total RNA extraction (250 000 cells in 12-well plate). 
Hepatocytes were also treated for 6 hours with 1 mM and 3 mM of citrate or water 
and collected for citrate measurements (750 000 cells in 6-well plate).  
 Fumaric acid, succinic acid, α-ketoglutaric acid disodium salt dihydrate, 
oxaloacetic acid and malic acid disodium salt were added to the cell culture medium 
at a final concentration of 1 mM or 3 mM. Hepatocytes were collected 3 hours, 6 
hours and 9 hours after treatment for total RNA extraction (250 000 cells in 12-well 
plate).  
   
2.5.4 Measurement of ACLY enzymatic activity   
 The enzymatic activity of ACLY was measured via the malate dehydrogenase-
coupled method in protein extracts as described before [139, 140]. Samples were 
homogenized in RC buffer and the supernatant was collected. Triton-X was added to 
a final concentration of 0.01% and the supernatant was incubated for 20 min on ice. 
200 µl of reaction mix (1 mM ADP, 10 mM potassium phosphate, 1 mM 
oxaloacetate, 0.25 mM acetyl-coA, 100 mM 5,5’-dithio-bis(2-nitrobenzoic acid) was 
added to 20 µl of the cell lysate and the absorbance was measured at 412 nm on 
kinetic mode (SpectraMax Plus 384, VWR). ACLY activity was calculated using the 
speed of reaction automatically measured by the spectrophotometer and normalized 
with regards to the total protein concentration in the cell lysate.  
 
2.5.5 Measurement of ACO1 and ACO2 enzymatic activities  
 The activity of cytosolic and mitochondrial aconitase was performed by using 
a colorimetric aconitase assay kit (Sigma-Aldrich) according to manufacture's 
instructions. Hepatocytes were homogenized in ice-cold assay buffer and centrifuged 
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to remove insoluble material. Half of the supernatant was directly used for the 
cytosolic aconitase assay whereas the remaining sample was re-centrifuged. The 
resulting pellet was dissolved in assay buffer, sonicated and used for the 
mitochondrial aconitase assay. All samples were activated by adding the aconitase 
activation solution and loaded into a 96-well plate. The reaction mix was added to 
every sample and standard and the absorbance was measured at 450 nm against blank 
in a spectrophotometer (SpectraMax-M2e, VWR). Calculation of the enzymatic 
activities based on the absorbance was made as indicated by the manufacturer. The 
activity of ACLY detected in each sample was normalized against the protein content. 
Protein concentration was determined directly from the cell extracts using the DC 
Protein assay from Bio-Rad  according to manufacturer's instructions. 
 
2.5.6 MTT assay  
 Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as described in literature but with some 
modifications [141]. 5 mg/ml of MTT solution was added to the culture and cells 
were incubated for 2 hours and 30 min at 37°C with 5% CO2. 10% SDS was added to 
the culture medium and cells were incubated for 16 hours at 37°C. The absorbance 
was measured at 570 nm in a spectrophotometer (SpectraMax-M2e, VWR) and the 
background absorbance at 690 nm was subtracted.  
 
2.5.7 Citrate measurements 
 Citrate measurements were performed by using a colorimetric citrate assay kit 
from Sigma-Aldrich according to manufacture's instructions. Hepatocytes (750 000 
cells) or tissues (about 20 mg) were homogenized in citrate assay buffer and 
centrifuged to isolate insoluble material. The supernatant and standards were added to 
the reaction mix and the absorbance was measured at 570 nm against blank in a 
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spectrophotometer (SpectraMax-M2e, VWR). Calculation of the citrate level based on 
the absorbance was made as indicated by the manufacturer. The citrate level in the 
cell extracts was normalized to the protein content. Protein concentration was 
determined directly from the cell extracts using the DC Protein assay from Bio-Rad 
according to manufacturer's instructions. The citrate level in extracts from liver was 
normalized to the tissue weight. 
 
2.5.8 RNA extraction, RT-PCR and quantitative real-time PCR 
 Total RNA was isolated from cells using the RNeasy Plus Mini kit (Qiagen) 
according to manufacturer’s instructions. Total RNA (500 ng) was reverse-transcribed 
in a 25 ml reaction mixture using RevertAid H Minus Reverse Transcriptase and 
random primers.  Total RNA was isolated from tissues by using TRIzol®Reagent 
according to manufacture's instructions. Approximately 20 mg of tissue was lysed in 
TRIzol and homogenized with 3 mm tungsten carbide beads in a tissue lyser 
(Qiagen). Total RNA was then purified by phenol-chloroform and washed with 70% 
ethanol. RNA (1 mg) was reverse-transcribed in a 25 ml reaction mixture using 
RevertAid H Minus Reverse Transcriptase and random primers. SYBR-green 
quantitative real-time PCR (qPCR) was performed using the ABI StepONE Plus real-
time PCR system with the primers listed in Table 2.1. Relative mRNA expression was 
normalized to Rpl19 (ribosomal protein L19) mRNA. Results were calculated by 
using the ΔΔCt method.  
 
2.5.9 Protein extraction and Western blot analysis 
 Proteins were extracted by lysing about 20 mg of tissue with RIPA buffer with 
1x protease inhibitor cocktail (Roche) and phosphatase inhibitors (Roche). After 30 
min, extracts were centrifuged to remove insoluble material and the supernatant was 
used to measure protein content. Protein concentration was determined by using the 
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DC Protein assay from Bio-Rad according to manufacturer's instructions. Cell protein 
extracts (80 mg) or tissue protein extract (50 mg) were then used for Western blot 
analysis. Extracts were mixed with 1x Laemmli buffer and boiled at 95 °C for 10 min. 
Proteins were separated by size in a 10% SDS-PAGE and transferred to a 
nitrocellulose membrane by a wet system. Membranes were blocked with 5% milk 
powder in TBS-0.1% tween for 1 hour at room temperature. Primary antibodies are 
listed in Table 2.2 and were incubated overnight at 4°C except for the vinculin 
antibody, which was incubated for 1 hour at room temperature. Membranes were 
washed with TBS-0.1% tween and incubated with anti-IgG of the respective source of 
production for 1 hour in 5% milk in TBS-0.1% tween (listed in Table 2.3). After 
washing, proteins were detected by using ECL-plus reagent and visualized with a 
Fusion FX system (Peqlab). Proteins were normalized to vinculin. Protein 
quantification was performed by using the ImageJ software available online 
(https://imagej.nih.gov/ij/).  
 
2.5.10 Tail vein injections 
 Mice were administered 10.5 mg of citrate/kg of body weight or vehicle (PBS) 
via the tail vein. The citrate concentration of the citrate solution used for the injections 
was 2 ng of citrate/ml of PBS pH 7.0 and the volume administered  in the mouse was 
an average of 130 µl. Mice were fasting for 4 hours before citrate or PBS 
administration and euthanized with isoflurane 2 hours after injections. The blood was 
removed by cardiac puncture and the liver was collected for downstream applications.  
 
2.5.11 Measurement of blood parameters 
 The blood was collected from PBS and citrate injected mice by cardiac 
puncture and added to tubes with heparin to prevent coagulation. All hematological 
parameters were determined by introducing each blood sample to the ScilVet ABC 
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blood analyzer machine. After measurement of hematological parameters, the blood 
was centrifuged 10 min at 2000xg to isolate plasma. The plasma was then collected to 
measure hepcidin levels. 
 
2.5.12 Measurement of hepcidin in the plasma 
 Hepcidin levels in the plasma were assessed by using the Hepcidin-Murine 
Compete ELISA (Intrinsic Lifesciences) according to manufacturer's instructions. 
After measuring the absorbance of the samples and standard, the levels of hepcidin 
were calculated based on the equation of a 4PL plot (curve expert program), as 
recommended, and represented as ng/ml. 
 
2.5.13 Statistical Analysis 
 Experiments with primary murine hepatocytes represent a mean of at least 3 
independent experiments. In vivo experiments are represented by mean of 8 mice per 
group in a total of two independent experiments. All graphs are represented as relative 
expression or fold-change plus standard error of the mean (SEM). A two-tailed 
Student’s t-test was used for estimation of statistical significance except for when 
more than one variable was being taken into consideration. In this case, a two-way 
ANOVA was used to estimate statistical significance. Data with a P value less than 
0.05 was considered significant (*P<0.05,**P<0.001,***P<0.0001).  
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3 Results  
3.1 Citrate metabolism cross-talks to the regulation of 
hepcidin mRNA levels 
 
 Genome-wide RNAi screens are a powerful technique to unveil new effectors 
involved in particular processes. The unbiased siRNA screen performed in HuH7 
cells in our laboratory identified about two thousand genes, which potentially affect 
hepcidin expression [95]. By applying DAVID analysis, the candidate hepcidin 
regulators were classified according to various annotation terms, including gene 
ontology and biochemical and signaling pathways. The DAVID analysis enabled the 
identification of metabolic processes contained within the putative regulators of 
hepcidin. These functional categories varied from broad to more specific and are 
represented in Table 3.1. 
 The "citrate metabolic process" category was selected for this study because i) 
citrate is central to energy metabolism, and ii) citrate is the substrate of the iron-
regulatory protein 1, involved in the regulation of cellular iron metabolism. This 
category was contained within the putative hepcidin activators and included three 
genes: ACO1 (cytosolic aconitase), ACO2 (mitochondrial aconitase) and ACLY 
(ATP citrate lyase). ACO1 and ACO2 metabolize citrate into iso-citrate in the cytosol 
and mitochondria, respectively, whereas ACLY produces oxaloacetate and acetyl-coA 
from citrate in the cytosol (reviewed in [114, 123]). I next set out to investigate 
whether perturbation of citrate metabolism influences hepcidin transcriptional control.  
 The screening data in HuH7 cells showed a validation rate of 50% [95]. I 
further validated the initial findings in HuH7 cells by using primary murine 
hepatocytes (PMH), which are a more physiological system compared to the cancer 
cell line HuH7 cell. 
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Table 3.1: List of enriched metabolic groups obtained from DAVID analysis of the RNAi 
screening data. Obtained from Mleczko-Sanecka et al, 2014. 
 
 To validate ACO1, ACO2 and ACLY as regulators of hepcidin, I first 
performed siRNA-mediated knockdown in PMH. As positive controls, components of 
the BMP/SMAD signaling pathway were subjected to RNAi. BMP receptor 
(BMPR1A) is an activator of hepcidin expression whereas SMAD7 is a negative 
control of the pathway [59, 62, 64]. Thus, hepatocytes from wild-type (WT) mice 
were transfected with a single scrambled siRNA, one single siRNA targeting Bmpr1a 
and Smad7 (positive controls) or two independent siRNAs each for Acly, Aco2 and 
Aco1. The scrambled siRNA was designed to present limited sequence similarity to 
known genes of the mouse and will be further referred to as unrelated control siRNA. 
The knockdown efficiency of each gene and endogenous hepcidin mRNA expression 
were determined by qPCR analysis. As depicted in Figure 3.1 (panel A), the 
knockdown of Bmpr1a (hepcidin activator) reduced hepcidin mRNA levels whilst 
Category - hepcidin activators No. of genes P value 
Macromolecule metabolic process 462 1.5x10-2 
Citrate metabolic process 3 1.2x10-2 
Protein metabolic process 237 2.2x10-2 
Porphyrin metabolic process 3 4.8x10-2 
Proton-transporting ATPase activity 5 8.8x10-2 
Cellular lipid metabolic process 21 1.6x10-2 
Lysophosphatase activity 4 5.5x10-2 
Fatty acid binding 7 6.0x10-2 
Category - hepcidin suppressors No. of genes P value 
Cellular lipid metabolic process 21 1.6x10-2 
Regulation of macromolecules metabolic process 25 4.4x10-2 
Fatty acid metabolism 4 7.6x10-2 
Carbohydrate metabolic process 18 9.3x10-2 
Vitamin A metabolic process 3 9.4x10-2 
Oxidoreductase activity, acting on NADH, 
NADPH, quinone or similar as acceptor 5 2.4x10
-2 
Regulation of catalytic activity 27 6.9x10-2 
Regulation of cell biosynthetic process 21 3.6x10-2 
Isoprenoid metabolic process 4 7.7x10-2 
NAD or NADH binding 4 8.9x10-2 
Acylglycerol metabolic process 4 9.9x10-2 
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knockdown of Smad7 (hepcidin repressor) resulted in an up-regulation of hepcidin 
mRNA expression. This result shows that the pathway that regulates hepcidin 
transcription in the liver is well preserved in primary hepatocytes. Knockdown of 
Acly, Aco2 and Aco1 significantly diminished Acly, Aco2 and Aco1 mRNA expression 
(to <25% of the control), which correlated with a significant increase in hepcidin 
mRNA expression (mean of 3-, 1.8- and 2-fold in Acly, Aco1, and Aco2 knockdown, 
respectively) (Figure 3.1, panel B). In the case of the Aco2 knockdown, only one 
siRNA was successful to alter hepcidin mRNA levels. Together, these results indicate 
that ACLY, ACO1 and ACO2 may be regulators of hepcidin expression in PMH. As 
shown in Table 3.1, Aco1, Aco2 and Acly are contained within the group of putative 
hepcidin activators in HuH7 cells. Therefore, it was expected that the knockdown of 
these genes would lead to the down-regulation of hepcidin mRNA expression. 
However, my data show that knockdown of Aco1, Aco2 and Acly up-regulates 
hepcidin in PMH. This discrepancy may be explained by the fact that primary cells 
show different physiology, which may have an impact on hepcidin regulation.   
 One disadvantage of using RNAi experiments is the possible occurrence of 
off-target effects. To consolidate my findings, I treated PMH with inhibitors of the 
enzymatic activities of ACLY, ACO1 and ACO2. The fetal bovine serum contains 
BMPs and other factors such as interleukins, which are known to strongly up-regulate 
hepcidin transcription (see Section 1.1.4). To avoid confounding effects of BMPs and 
interleukins on hepcidin mRNA expression, all subsequent experiments were 
performed without addition of serum to the cell culture medium.  
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Figure 3.1: Inhibition of the activity of enzymes involved in citrate metabolism alters 
hepcidin mRNA levels in primary murine hepatocytes. 
A) Hepatocytes were transfected with an unrelated control siRNA or siRNAs for Bmpr1a or 
Smad7 for 72 hours; top graph: mRNA analysis of Bmpr1a and Smad7; bottom graph: mRNA 
analysis of hepcidin; B) PMH were transfected with an unrelated siRNA or 2 independent 
siRNAs (#1 and #2) for Acly, Aco1 or Aco2 for 72 hours; top graph: mRNA analysis of Acly, 
Aco1 and Aco2; bottom left and right graphs: mRNA analysis of hepcidin. C) PMH were 
starved from serum for one hour and treated for 90 min with 50 µM of the ACLY inhibitor 
(BMS-30314); left graph: measurement of the activity of ACLY; right graph: analysis of the 
hepcidin mRNA level. D) Hepatocytes were starved from serum for one hour and treated for 
3 hours with 3 mM of citramalate (inhibitor of the activity of aconitases); left graph: 
measurement of the activities of the cytosolic and mitochondrial aconitase; right graph:  
hepcidin mRNA levels analysis; Rpl19 was used as reference gene. Data are represented as 
fold-change (+SEM) compared to the control except for the left graph in panel C, which is 
represented as optical density/minute normalized against the protein content (+SEM). 
Significant changes are marked with *(P<0.05), **(P<0.001) and ***(P<0.0001). ns - not 
significant.  
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 The commercially available compound BMS-30314 has been described as an 
inhibitor of the ATP citrate lyase activity [142] in vitro and in vivo. Consistently, 
treatment of hepatocytes with this inhibitor resulted in a 50% decrease of ACLY 
activity (Figure 3.1, panel C, left graph). Concomitantly, the hepcidin mRNA level 
was elevated by 3.4-fold (Figure 3.1, panel C, right graph). The measurement of the 
ACLY activity was done in collaboration with Dr. Sven W. Sauer (University of 
Heidelberg). Citramalate has been suggested to be an inhibitor of the activity of 
mitochondrial aconitase in plants [143]. Curiously, PMH treated with citramalate 
showed reduced activity of both cytosolic and mitochondrial aconitase, 35% and 40% 
of inhibition respectively (Figure 3.1, panel D, left graph). In this condition, hepcidin 
mRNA expression was significantly up-regulated (Figure 3.1, panel D, right graph). 
These results support the data from the RNAi experiments in PMH, which identified 
ACLY, ACO1 and ACO2 as suppressors of hepcidin mRNA expression.  
 All together, these results show that citrate metabolism cross-talks to hepcidin 
expression as both suppression of the mRNA levels and inhibition of the enzymatic 
activity of ACLY, ACO1 and ACO2 leads to the increase in hepcidin mRNA levels. 
 
3.2 Increased intracellular citrate levels regulate 
hepcidin mRNA expression  
 
 Cytosolic aconitase (ACO1), mitochondrial aconitase (ACO2) and ATP citrate 
lyase (ACLY) are enzymes that catalyze citrate-consuming reactions. ACO1 and 
ACO2 convert citrate into iso-citrate in the cytosol and mitochondria respectively, 
and ACLY metabolizes citrate into acetyl-coA and oxaloacetate in the cytosol 
(reviewed in [114, 122]). I have shown that inhibition of cytosolic and mitochondrial 
aconitases as well as of the ATP citrate lyase results in the up-regulation of hepcidin 
mRNA expression. If these three enzymes function by consuming citrate and 
converting it into other intermediates, it is tempting to hypothesize that the inhibition 
of their activity would lead to the accumulation of citrate in the cell. In fact, it has 
been described that the siRNA-mediated knockdown of Acly in cells increases 
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intracellular citrate levels [144]. It has also been shown that prostate cells show high 
citrate levels due to limiting activity of mitochondrial aconitase ([145] and reviewed 
in [146]). In addition, treatment of plants with citramalate (mitochondrial aconitase 
inhibitor) results in increased citrate levels in fruits [143]. Furthermore, isolated cells 
from citrus fruit calli grown in iron-free soil show elevated citrate levels compared to 
cells grown in iron-rich soil [147]. This is most likely due to reduced aconitase 
activity of IRP1 upon iron-deficiency [147]. Therefore, I tested whether increasing 
citrate levels in cells by supplementing citrate in the medium would up-regulate 
hepcidin mRNA expression in PMH.  
 Hepatocytes from WT mice either remained untreated or were treated with 1 
mM and 3 mM of citrate. 3, 6 and 9 hours after treatment PMH were collected for 
further analyses. As depicted in Figure 3.2 (panel A, left graph), hepatocytes 
supplemented with citrate in the cell culture medium significantly up-regulated the 
mRNA expression of hepcidin up to 3.8-fold in a time- and dose-dependent fashion.  
 To investigate whether the hepcidin-response to citrate requires citrate uptake, 
I measured citrate levels in PMH untreated or treated with 1 mM or 3 mM of citrate 
for 6 hours. At this time-point hepcidin mRNA levels start to be strongly and 
significantly increased. As shown in Figure 3.2 (panel A, middle graph), intracellular 
citrate levels were significantly elevated in a dose-dependent manner compared to the 
control. The intracellular citrate concentration varies from 100-400 µM (up to 4x 
more) in mammalian cells [145]. The fact that citrate levels only increased by less 
than 1.5-fold after 6 hours of citrate supplementation compared to control, shows that 
citrate in PMH increased within the physiological range.  
 Citrate can reduce cell viability in high doses. For instance, cancer cells 
treated with citrate concentrations of 10-20 mM show a dramatic reduction of cell 
viability 24 hours after treatment [148, 149]. To analyze whether citrate 
supplementation reduces cell viability in PMH, I determined the cell viability by the 
methyl-thiazolyl-tetrazolium bromide (MTT) assay. The MTT assay is based on the 
ability of living and metabolically active cells to cleave the MTT into formazan, thus, 
the cell viability and degree of activation is proportional to the production of 
formazan. Due to its colorimetric property, formazan can be quantified by a 
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spectrophotometer [150]. As shown in Figure 3.2 (panel A, right graph), treatment of 
hepatocytes with 1 mM or 3 mM of citrate for 3, 6 or 9 hours does not result in a 
significant decrease in cell viability.    
 
   
 
Figure 3.2: Increased intracellular citrate levels activate hepcidin expression. 
A) left graph: hepcidin mRNA analysis of PMH treated with 1 mM or 3 mM of citrate for 3, 6 
and 9 hours; middle graph: measurement of intracellular citrate levels of hepatocytes treated 
with 3 mM of citrate for 6 hours; right graph: analysis of cell viability by the MTT assay after 
treatment with 1 mM or 3 mM of citrate for 3, 6, and 9 hours; B) Hepatocytes were 
transfected with an unrelated control siRNA or siRNAs for Nact and Nadc3 for 39 hours 
followed by 5 mM citrate treatment for further 9 hours. left graph: mRNA analysis of Nact 
and Nadc3; right graph: mRNA analysis of hepcidin. Rpl19 was used as reference gene. Data 
are represented as fold-change (+SEM) compared to the control or as relative expression 
(Hamp1/Rpl19) (+SEM). Significant changes are marked with *(P<0.05), **(P<0.001) and 
***(P<0.0001). ns - not significant. 
 
 The results presented above (Figure 3.2, panel A) show that hepatocytes 
externally treated with citrate up-regulate hepcidin mRNA expression likely due to 
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increased intracellular citrate concentration. If this is the case, inhibition of citrate 
uptake should prevent the citrate-induced hepcidin mRNA increase. Citrate is taken 
up in different cell types via the sodium-coupled dicarboxylate and citrate 
transporters, members of the SLC13 family. These plasma membrane transporters 
import citrate as well as other metabolites generated in the citric acid cycle with 
different affinities (reviewed in [151]). Particularly in the liver, the NaCT transporter 
(SLC13A5) is expressed in the sinusoidal membrane of hepatocytes [152] and shows 
high affinity for citrate whilst it transports succinate and malate with lower affinity 
[152, 153]. The NaDC3 (SLC13A3) transporter is also expressed in hepatocytes 
[154], however it has equal affinity for a wider range of citric acid cycle components. 
It transports citrate, succinate, fumarate, malate, oxaloacetate and α-ketoglutarate 
[155].  
 The citrate transporters NaCT and NaDC3 are expressed in hepatocytes [151, 
152]. I next transfected PMH with either an unrelated control siRNA or siRNAs 
targeting the Nact and Nadc3 mRNAs. A concentration of 3 mM citrate was applied 
in the time course supplementation experiment shown in Figure 3.2 (panel A). 
Because 3 mM citrate treatment in combination with siRNA-mediated transfections 
does not significantly alter the hepcidin mRNA expression (data not shown), a higher 
concentration of citrate was used. 39 hours after RNAi transfection, hepatocytes were 
treated with 5 mM citrate for a further 9 hours. The knockdown of Nact and Nadc3 
significantly reduced the expression of Nact and Nadc3 (to 10% and 25% of the 
control respectively) (Figure 3.2, panel B, left graph). As represented in Figure 3.2 
(panel B, right graph), hepatocytes transfected with a control siRNA responded to 
citrate by significantly up-regulating hepcidin mRNA expression (from a relative 
expression of 0.8 to 2.2). However, the knockdown of Nact+Nadc3 attenuated the 
increase of hepcidin mRNA levels from 0.7 to 1.2 in response to citrate. The 
knockdown of Nact+Nadc3 in absence of citrate treatment does not have any impact 
on hepcidin mRNA levels. These results show that the citrate transporters are 
necessary for the response of hepcidin to citrate.  
 The citrate transporters NaCT and NaDC3 transport other intermediaries of 
the citric acid cycle [151, 152]. To test whether succinate, malate, fumarate, α-
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ketoglutarate and oxaloacetate have a role in regulating hepcidin expression, I treated 
PMH with 1 mM or 3 mM of these compounds for 3, 6 and 9 hours. As shown in 
Figure 3.3, hepcidin mRNA expression did not change with these treatments except 
for malate in one particular concentration and time-point (3 mM, 6 hours). Therefore, 
I conclude that the response of hepcidin to the supplementation of intermediaries of 
the citric acid is specific for citrate.  
 
 
Figure 3.3: Citrate specifically regulates hepcidin mRNA levels. 
mRNA analysis of PMH treated with 1 mM or 3 mM of α-ketoglutarate, malate, oxaloacetate, 
fumarate or succinate for 3, 6 and 9 hours. Rpl19 was used as reference gene. The data is 
represented as fold-change (+SEM) compared to the control. Significant changes are marked 
with *(P<0.05).  
 
3.3 The hepcidin response to citrate involves the 
BMP/SMAD signaling pathway 
 
 The BMP/SMAD signaling pathway controls hepcidin activation in response 
to iron levels and inflammatory stimuli [59, 83]. Furthermore, suppression of hepcidin 
mRNA levels by the nutrient-sensing mTOR signaling pathway requires functional 
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BMPREs, suggesting the involvement of the BMP/SMAD pathway in this response 
[95]. When this pathway is activated, BMPR1A induces the phosphorylation of the 
SMAD1/5/8 proteins, which then associate with the co-activator SMAD4, and bind to 
the promoter of hepcidin [57, 63]. 
 Since the BMP/SMAD signaling pathway regulates hepcidin expression upon 
a variety of stimuli, I investigated whether the BMP/SMAD signaling pathway 
mediates the response of hepcidin to citrate. To test this hypothesis I first analyzed the 
mRNA expression of Id1 in RNA samples from PMH treated with citrate for 3, 6 and 
9 hours (the same samples used to generate the graph in Figure 3.2, panel A). Id1 is a 
target gene of BMP/SMAD signaling and it is co-regulated with hepcidin following 
pathway stimulation [63]. Although the gene response pattern of Id1 differed from the 
one of hepcidin (Figure 3.2, panel A, left graph), the mRNA of Id1 was significantly 
up-regulated upon citrate treatment (Figure 3.4, panel A). The data suggest that the 
BMP/SMAD signaling pathway plays a role in regulating hepcidin upon citrate 
supplementation.  
 To understand the involvement of the BMP/SMAD signaling pathway in the 
citrate-mediated hepcidin response, I transfected PMH either with an unrelated 
control siRNA or with siRNAs targeting Bmpr1a, Smad4 and Smad1 mRNAs, and 
either treated cells or not with citrate for 9 hours. The knockdown of the Bmpr1a, 
Smad4 and Smad1 mRNAs resulted in the reduced mRNA expression of the Bmpr1a, 
Smad4 or Smad1 genes (to 10%, 5% and 15% of the control, respectively) (Figure 
3.4, panel B) and in decreased levels of hepcidin mRNA (Figure 3.4, panel C). This 
result shows that the hepatocytes correctly responded to stimuli that regulate hepcidin 
expression. Consistent with previous results (Figure 3.2), PMH transfected with 
control siRNA and treated with citrate responded by significantly increasing hepcidin 
mRNA levels (Figure 3.4, panel C). However, knockdown of Bmpr1a, Smad4 and 
Smad1 resulted in a complete inability of hepcidin to respond to citrate (Figure 3.4, 
panel C). These results show that the BMP pathway either is mediating the response 
of hepcidin or must be functional for hepcidin to be regulated by citrate.  
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Figure 3.4: BMP/SMAD signaling and the hepcidin response to citrate. 
A) Id1 mRNA analysis of PMH treated with 3 mM of citrate for 3, 6 and 9 hours. 
Hepatocytes were transfected with an unrelated control siRNA or siRNAs for Bmpr1a, Smad4 
and Smad1 for 39 hours following 9 hours of treatment with 5 mM of citrate. B) Cells were 
analyzed for the mRNA expression of Bmpr1a (left graph), Smad4 (middle graph), Smad1 
(right graph). C) Cells were analyzed for the mRNA expression of hepcidin. Rpl19 was used 
as reference gene. Data are represented as fold-change (+SEM) compared to the control or in 
relative expression (Hamp1/Rpl19) (+SEM). Significant changes are marked with *(P<0.05), 
**(P<0.001) and ***(P<0.0001). ns - not significant. 
 
 To analyze whether the BMP/SMAD signaling pathway has an active role in 
regulating hepcidin upon citrate treatment, I treated PMH with citrate for 90 min, 3 
hours and 6 hours, and performed Western blot analysis to detect the phosphorylation 
level of the SMAD1/5/8 transcription factors. The phosphorylation status of these 
proteins indicates the degree of activation of the BMP/SMAD pathway. 
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Unfortunately, phosphorylated SMAD proteins in extracts from untreated or citrate-
treated cells were not detectable (data not shown). This may be explained by the fact 
that the citrate supplementation experiments were performed under serum-free 
conditions, which lack basal stimulators of this pathway that would usually be present 
in the serum. Without these stimulators, most likely the phosphorylation level of the 
SMAD proteins was below the limit of detection. 
 
 
               
Figure 3.5: The response of hepcidin to citrate is independent of HJV and HFE proteins. 
Hepatocytes were transfected with an unrelated control siRNA or siRNAs for Hjv and Hfe for 
39 hours following 9 hours of treatment with 5 mM of citrate or water. Cells were analyzed 
for the mRNA expression of A) left graph: Hjv, right graph: hepcidin; B) left graph: Hfe; right 
graph: hepcidin. The Rpl19 gene was used a reference. Data are represented as fold-change 
(+SEM) compared to the control or in relative expression (Hamp1/Rpl19) (+SEM). 
Significant changes are marked with *(P<0.05), **(P<0.001) and ***(P<0.0001). ns - not 
significant. 
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 The hemochromatosis proteins HFE and HJV are important upstream 
activators of hepcidin by the BMP/SMAD signaling pathway. HJV is a BMP co-
receptor [67], which regulates the activity of the pathway [68], and HFE is known to 
stabilize the BMPR1A [75]. I next investigated whether the citrate response of 
hepcidin requires HFE and HJV. PMH were transfected with siRNAs targeting Hjv 
and Hfe, as well as a control siRNA, and were either treated or not with citrate for 9 
hours. The mRNA levels of Hjv, Hfe and hepcidin were analyzed by qPCR. The 
mRNA expression of both Hjv and Hfe genes upon siRNA transfection was 
significantly reduced to at least 25% of the control, showing that the knockdown of 
these genes was efficient (Figure 3.5, panel A and B, left graphs). Reflecting the role 
of HFE and HJV as hepcidin activators, the reduction in Hjv and Hfe mRNA resulted 
in decreased hepcidin expression (Figure 3.5, panel A and B, right graphs). Consistent 
with previous experiments (Figures 3.2 and 3.4), hepatocytes transfected with an 
unrelated control siRNA and treated with citrate increased hepcidin expression. 
Interestingly, upon Hjv and Hfe knockdown, the hepcidin response to citrate was 
similar to that of control siRNA-transfected cells without citrate treatment (Figure 3.5, 
panel A and B, right graphs). This result suggests that the regulation of hepcidin 
expression in response to citrate is independent of the HFE and HJV proteins.  
 My data show that the BMP/SMAD signaling pathway is involved in 
regulating the hepcidin response to citrate (Figure 3.4). Several ligands have been 
identified to bind to BMP receptors and stimulate hepcidin expression. These ligands 
include BMP6, BMP4, BMP7, BMP9 and TGF-β [59, 156-158]. To investigate 
whether altered expression levels of BMP ligands play a role in the hepcidin response 
to citrate, I performed qPCR analysis of Bmp6, Bmp4, Bmp9, Bmp7 and Tgfb1 in total 
RNA extracts from hepatocytes treated with citrate for 3, 6 and 9 hours. Bmp6 mRNA 
expression was not detected in control or citrate-treated PMH. As shown in Figure 3.6 
(panel A), Bmp4 was significantly regulated and follows an expression pattern that 
could be correlated with the pattern of hepcidin expression in the same conditions 
(Figure 3.2, panel A, left graph). The mRNA levels of Bmp9, Bmp7 and Tgfb1 did not 
significantly change when treated with citrate (Figure 3.6, panel A). 
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Figure 3.6: The hepcidin response to citrate is independent of BMP6, BMP4, BMP7, 
BMP9 and TGF-β . 
A) RNA extracts from PMH treated with water of citrate for 3, 6 and 9 hours were analyzed 
for the mRNA expression of Bmp4, Bmp7, Bmp9 and Tgfb1. B) Hepatocytes were transfected 
with an unrelated control siRNA or siRNA for Bmp4 for 39 hours following 9 hours of 
treatment with 5 mM of citrate or water. Cells were analyzed for the mRNA expression of 
Bmp4 (left graph) and hepcidin (right graph). The Rpl19 gene was used as reference. Data are 
represented as fold-change (+SEM) compared to the control or in relative expression 
(Hamp1/Rpl19) (+SEM). Significant changes are marked with *(P<0.05), **(P<0.001) and 
***(P<0.0001). ns - not significant.  
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 To test whether BMP4 is involved in the citrate response of hepcidin, I 
performed siRNA-mediated knockdown of Bmp4 in PMH under control conditions or 
upon citrate treatment. The mRNA expression of hepcidin was then analyzed by 
qPCR (Figure 3.6, panel B).  
 As depicted in Figure 3.6 (panel B, left graph), the knockdown of the Bmp4 
significantly decreased the mRNA level of Bmp4, showing that its knockdown was 
efficient. Consistent with BMP4 being an activator of hepcidin, the knockdown of 
Bmp4 resulted in a decrease in hepcidin expression (Figure 3.6 panel B, right graph). 
Although the mRNA levels of Bmp4 were diminished upon knockdown, the hepcidin 
gene responded similarly to citrate treatment both in control siRNA- or Bmp4 siRNA-
transfected hepatocytes (approximately 3-fold increase) (Figure 3.6, panel B, right 
graph). This result suggests that the hepcidin response to citrate does not involve 
BMP4.  
 
 
3.4 Citrate regulates hepcidin mRNA expression in 
mice  
 
 The cell-based experiments (presented above) show that citrate 
supplementation increases hepcidin mRNA expression in primary murine hepatocytes 
and that the hepcidin response to citrate is mediated by the BMP/SMAD signaling 
pathway. I next investigated whether citrate induces hepcidin expression in the mouse 
liver and if this response involves BMP/SMAD signaling. Citrate levels in 
hepatocytes in vivo were increased by administering citrate to WT mice. Hepcidin 
mRNA levels in the liver and plasma, as well as hematological parameters, were 
assessed.  
 Tail vein injection was chosen as the route for citrate administration in mice. 
The LD50 for citric acid has been reported to be 42 mg/kg body weight [159]. To 
avoid possible hepatic and extra-hepatic toxicity, we intravenously injected 10.5 mg 
of citric acid/kg body weight. This dose is 4-fold lower than the LD50 and has been 
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discussed and approved by the EMBL institutional Animal Care and Use Committee. 
Mice used for the intravenous injection experiments weighed approximately 23 g and 
were injected with approximately 130 µl of PBS or citrate (below the maximum 
volume allowed to inject iv in mice). Klaus Schmitt from the EMBL Laboratory for 
Animal Resources (LAR) performed the tail vein injections. Mice were fasting for 4 
hours before injection and were euthanized 2 hours after citrate or PBS injections for 
blood and organ collection. 
 To address whether citrate administration leads to changes in the blood 
chemistry, I measured hematological parameters in citrate- and PBS-injected mice 
(Table 3.2). As a marker for inflammation, I analyzed the number of white blood cells 
(WBC), which showed comparable numbers in PBS- and citrate-injected mice. As 
markers for red blood cell disruption, I analyzed red blood cell number (RBC), mean 
corpuscular volume (MCV), concentration of hemoglobin, hematocrit and red blood 
cell distribution (RDW). Similar values for RBC, MCV, RDW revealed that there 
were no changes in red blood cell numbers upon citrate injection. Together, these 
results show that citrate did not disrupt blood cells nor induced inflammation at the 
time point studied. This finding is particularly important because hepcidin is regulated 
by inflammation and erythropoietic activity (see Section 1.1.4 for more details). 
Therefore, as RBC and WBC numbers do not change in either PBS- or citrate-injected 
mice, an erythropoietic and inflammatory stimulus to regulate hepcidin expression 
upon citrate treatment can be excluded. 
  To test whether citrate levels increased in the liver following tail vein 
injections, I performed citrate measurements in the liver from PBS- and citrate-
injected mice. I found that citrate levels were significantly increased by 2-fold in the 
liver (Figure 3.7, panel A). As intracellular citrate concentrations vary from 100-400 
mM in mammalian cells [145], the observation that citrate levels increased by 2-fold 
after injection of citrate compared to control mice show that citrate in the liver 
increased within the physiological range. Concomitant with the citrate increase in the 
liver, hepcidin was significantly up-regulated at the mRNA level in the liver (>2-fold) 
and at the protein level in the plasma of citrate-injected mice (Figure 3.7, panel B). 
These results confirm my observations in cells (shown in Figure 3.2), in which 
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supplementation of citrate in the cell culture medium resulted in the accumulation of 
citrate in primary hepatocytes and in increased hepcidin expression. 
 
Table 3.2: Blood parameters measured in PBS- and citrate-injected mice. 
WBC = white blood cells, RBC = red blood cells, MCV = mean corpuscular volume, RDW = 
red cell distribution, hemoglobin concentration. 
 
 
Blood Parameter PBS (n=5) Citrate (n=6) P value 
WBC count (109/L) 4.62 ± 1.90 4.67 ± 1.18 0.969 
RBC count (1012/L) 10.87 ± 0.64 10.65 ±  0.21 0.781 
MCV (fL) 52.40 ± 0.55 53.00 ± 1.10 0.296 
Hemoglobin (g/L) 16.58 ± 0.94 16.62 ± 0.26 0.924 
Hematocrit (%) 56.16 ± 3.21 56.56 ± 1.39 0.815 
Platelet count (109/L) 1177.60 ± 473.06 1191.20 ± 223.27 0.414 
RDW (%) 13.36 ± 0.21 13.36 ± 0.18 0.984 
 
 
 The data from the cell-based experiments (Figure 3.4) suggests that the 
hepcidin response to citrate is controlled by the BMP/SMAD signaling pathway. In 
order to test if the response of hepcidin to citrate in mice also involved the 
BMP/SMAD signaling pathway, I analyzed the mRNA expression of the Id1 gene, 
which is co-expressed with hepcidin and is a target gene of the BMP/SMAD pathway 
[63]. In agreement with the in vitro experiments (Figure 3.4), the mRNA of ld1 was 
significantly up-regulated in citrate injected mice (Figure 3.7 panel C), further 
substantiating the involvement of the BMP/SMAD pathway in the response to citrate. 
 If the response of hepcidin to citrate in mice involves the BMP/SMAD 
pathway, then the phosphorylation of the SMAD1/5/8 proteins should be increased 
upon citrate injection. To test this, I performed Western blot analysis of p-
SMAD1/5/8 as well as the total levels of the SMAD1 protein. The analysis of the total 
levels of SMAD1 was performed to test whether alterations in the protein band of p-
SMAD1/5/8 may be due to changes in SMAD1 total levels. As shown in the Figure 
3.7 (panel D), the total levels of the SMAD1 protein were unchanged whilst the 
phosphorylation of p-SMAD1/5/8 increased in citrate-injected mice.  
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Figure 3.7: Mice injected with citrate via the tail vein present elevated citrate in the liver 
and induce hepcidin expression via the BMP/SMAD signaling pathway. 
Mice were deprived from food for 4 hours, injected with PBS or citrate and blood and liver 
were collected 2 hours after injections; A) Citrate measurements in the liver; B) Hepcidin 
mRNA analysis from total RNA from liver (left graph) and measurements of plasma hepcidin 
(right graph); C) mRNA analysis of Id1 in total RNA rom liver. The Rpl19 gene was used as 
reference. Data are represented as fold-change (+SEM) compared to the control. D) Western 
blot analysis of p-SMAD1/5/8 and SMAD1. Vinculin was used a loading control (left graph), 
quantification of the Western blot signals for p-SMAD1/5/8)/SMAD1 (right graph). 
Quantification was performed by using the software ImageJ. Significant changes are marked 
with *(P<0.05) and **(P<0.001). ns - not significant. 
 
 The quantification of the phosphorylation of the p-SMAD1/5/8 proteins was 
determined by using the ImageJ software. The area of each band of SMAD1 and p-
SMAD1/5/8 was determined and divided by the respective area of the loading control 
(vinculin). Subsequently, the normalized p-SMAD1/5/8 areas were divided by the 
normalized SMAD1 areas. This normalization allowed for the determination of the 
proportion of phosphorylated SMAD proteins relative to the levels of total SMAD1 
protein. The quantification of the p-SMAD1/5/8 proteins shows that the increase in 
phosphorylation of these proteins was significantly increased in citrate-injected mice. 
This result indicates that the BMP/SMAD pathway was more active in mice injected 
  Results 
57 
with citrate and that the response of hepcidin to citrate appears to involve this 
pathway.  
 All together, my results show that citrate regulates the mRNA expression of 
hepcidin via the BMP/SMAD signaling pathway in vitro and in vivo.
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4 Discussion and Conclusions 
 The regulation of iron homeostasis and cellular metabolism are functionally 
connected. Iron is a cofactor necessary for the activity of heme- (e.g hemoglobin, 
cytochromes) and non-heme-iron containing proteins (e.g. ribonucleotide reductase, 
amino-acid oxidases, lipoxygenases) ([127, 128] and reviewed in [2]). It further 
regulates the expression of enzymes necessary for metabolic processes (e.g. δ-
aminolevulinate synthase 2, mitochondrial aconitase, citrate synthase) [124-126]. 
Cathecolamines that stimulate energy metabolism also increase intracellular iron 
levels [129], whilst the mTOR signaling pathway (which responds to nutrient signals) 
increases iron uptake, reduces the assembly of Fe-S clusters and suppresses hepcidin 
expression [95, 131, 132]. In addition, proliferative stimuli and gluconeogenesis 
suppress hepcidin expression [95, 96]. Furthermore, citrate metabolism cross-talks to 
iron homeostasis due to the function of ACO1/IRP1 as a cytoplasmic aconitase under 
iron-replete conditions (reviewed in [123]). Specifically, the function of ACO1/IRP1 
as an iron-regulatory protein or as an aconitase is determined by the presence or 
absence of Fe-S clusters that are essential for the catalytic activity of this enzyme in 
all organisms [160]. While the effect that iron has on the function of ACO1/IRP1 is 
well understood, little is known about the contribution of citrate, the substrate of this 
enzyme, to iron homeostasis. In this work I describe for the first time a link between 
citrate metabolism and the expression of hepcidin, the master regulator of systemic 
iron homeostasis.  
 I was able to shown that the siRNA-mediated knockdown of enzymes that 
catalyze citrate-consuming reactions such as ACO1 (cytosolic aconitase), ACO2 
(mitochondrial aconitase) and ACLY (ATP citrate lyase), as well as the inhibition of 
their enzymatic activities by small molecules, increases hepcidin mRNA expression in 
primary murine hepatocytes (Figure 3.1). Accordingly, treatment of primary 
hepatocytes with citrate results in the increase of citrate levels in cells, which 
correlates with elevated hepcidin expression in a time- and dose-dependent manner 
(Figure 3.2). I further provide evidence that citrate acts intracellularly to regulate 
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hepcidin expression (Figure 3.2) and that the hepcidin response to intermediaries of 
the citric acid cycle is specific for citrate (Figure 3.3). I show that the BMP/SMAD 
signaling pathway mediates the response of hepcidin to citrate in primary hepatocytes 
(Figure 3.4), and that HFE and HJV are not required for this response (Figure 3.5). 
Consistent with the cell-based experiments, citrate injection via the tail vein in mice 
results in the increase of citrate in the liver as well as the up-regulation of hepcidin 
expression both at mRNA and protein level (Figure 3.7). Finally, I demonstrate that 
injection of citrate in mice leads to the increase in SMAD1/5/8 phosphorylation 
(Figure 3.7), an indicator for activated BMP/SMAD signaling.  
 
              
Figure 4.1: Working model. 
Citrate levels increase intracellularly by either inhibition of ACO1 (by siRNA/citramalate), 
ACO2 (by siRNA/citramalate) and ACLY (by siRNA/BMS303-14), or extracellular 
supplementation. Increased citrate levels lead to the activation of hepcidin expression via the 
BMP/SMAD signaling pathway. The link between citrate and the BMP/SMAD pathway 
remains to be elucidated. TCA cycle - citric acid cycle, ETC - electron transport chain. 
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 As summarized in Figure 4.1, my data show that the possible intracellular 
increase of endogenous citrate levels, either by the mRNA knockdown (siRNA) of 
ACO1, ACO2 and ACLY or inhibition of their enzymatic activities (citramalate and 
BMS-30314), as well as by the extracellular supplementation of citrate increases 
hepcidin expression. The hepcidin response to citrate involves the BMP/SMAD 
signaling pathway in vitro and in vivo. However, how intracellular citrate would 
increase the phosphorylation of the SMAD1/5/8 proteins remains to be elucidated.  
 
Citrate as a regulator of gene expression 
 The knockdown and the enzymatic inhibition of enzymes that catalyze citrate-
consuming reactions (ACO1, ACO2 and ACLY) increase hepcidin mRNA expression 
in primary murine hepatocytes. It has been described that the inhibition of these 
enzymes results in an increase of citrate levels in cells [143-147]. Therefore, it is 
likely that hepcidin expression is regulated due to increased citrate levels. 
Accordingly, treatment of PMH and mice with citrate results in increased citrate 
levels in hepatocytes and liver cells, respectively, as well as in increased expression of 
hepcidin. The ability of citrate to regulate gene expression is an aspect that is well 
established. Mitochondria-derived citrate can be detected in the nucleus, which serves 
as a substrate for ACLY to provide acetyl-coA for acetylation reactions. Lysine 
acetyl-transferases utilize acetyl-coA as a cofactor to donate acetyl groups to lysine 
residues present in histones (reviewed in [121, 161]). This results in the relaxation of 
chromatin and in the up-regulation of genes involved in metabolic processes [122] 
(see Section 1.1.2 for more detail). Interestingly, work published by Miura et al [162] 
and work under revision by Pasricha, S-R et al [163] show that hepcidin expression is 
regulated by histone acetylation. Inhibition of ACLY may result in reduced acetyl-
coA levels, while citrate accumulation may provide acetyl-coA for the acetylation of 
histones. However, both inhibition of ACLY (Figure 3.1) and supplementation with 
citrate (Figure 3.2) induce hepcidin expression in primary hepatocytes. Therefore, the 
results presented here do not suggest that hepcidin is regulated by citrate due to 
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chromatin remodeling. Thus, I hypothesize that a new role of citrate in regulating 
gene expression independent of histone acetylation may exist.  
 My data show that citrate acts intracellularly to regulate hepcidin expression 
(Figure 3.2) and that the hepcidin response to intermediaries of the citric acid cycle 
(which can be imported by the same plasma transporters) is specific for citrate (Figure 
3.3). I speculate that an active role of citrate as an "effector" molecule that integrates 
energy metabolism and gene expression, a feature that other intermediaries of the 
citric acid cycle do not share (reviewed in [114, 115, 121]), may contribute to increase 
hepcidin mRNA expression. 
 
The response of hepcidin to citrate involves the BMP/SMAD signaling pathway 
and is independent of HFE and HJV 
 I further explored the signaling pathway that mediates the response of 
hepcidin to citrate. I have shown that the knockdown of Bmpr1a, Smad4 and Smad1 
leads to the reduced response of hepcidin to citrate compared to the control (Figure 
3.4), suggesting the involvement of the BMP/SMAD signaling pathway. Although 
HFE and HJV are co-activators of the BMP/SMAD signaling pathway, knockdown of 
Hfe and Hjv do not affect the hepcidin response to citrate (Figure 3.5). Thus, the 
BMP/SMAD signaling pathway does not require HFE and HJV for its citrate 
response. The mRNA expression of hepcidin was significantly reduced upon siRNA-
mediated knockdown of Bmpr1a, Smad4, Smad1, Hfe and Hjv. This result is 
consistent with the fact that BMPR1A, SMADs and HFE/HJV are strong activators of 
hepcidin mRNA expression. Importantly, the response of hepcidin to citrate was 
selectively reduced upon knockdown of Bmpr1a, Smad4 and Smad1 compared to 
control siRNA. It is possible that the reduced effect of citrate on hepcidin expression, 
upon knockdown of Bmpr1a, Smad4 and Smad1, could be due to the diminished 
strength of the BMP/SMAD signaling pathway. However, upon knockdown of Hfe 
and Hjv, the response of hepcidin to citrate was similar to the control knockdown. 
Therefore, the decreased levels of hepcidin upon knockdown of these hepcidin 
activators do not per se determine the strength of the hepcidin response to citrate. I 
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believe that the weaker response of hepcidin to citrate upon knockdown of Bmpr1a, 
Smad4 and Smad1 is due to their specific involvement in mediating this response. In 
addition, the idea that the BMP/SMAD signaling pathway is involved in the hepcidin 
response to citrate is supported by the demonstration of increased phosphorylation of 
SMAD1/5/8 after citrate injection in vivo.  
 To better understand the involvement of the BMP/SMAD signaling pathway 
in the citrate-induced up-regulation of hepcidin, I am currently optimizing the 
conditions for chromatin immunoprecipitation (ChIP) analysis of SMAD1. ChIP 
analysis will enable me to assess whether there is an increase in the SMAD1 
transcription factor occupancy on the hepcidin promoter upon citrate treatment.  
 The fact that citrate involves the BMP/SMAD signaling pathway to regulate 
the expression of hepcidin raises the question of how citrate stimulates the 
BMP/SMAD signaling pathway. It is known that citrate can bind allosterically to 
proteins, such as PFK1 [164, 165] and F1,6BPase [166, 167]. Thus, I postulate that 
citrate may bind to proteins involved in the BMP/SMAD signaling pathway and 
potentiate either the interaction of p-SMAD1/5/8 with SMAD4 or mediate the 
translocation of this protein complex to the nucleus. An alternative hypothesis may be 
that citrate stimulates the mRNA expression of inducers of the BMP/SMAD signaling 
pathway in liver cells. Here I demonstrate that the BMP4 ligand of BMP receptors 
show increased mRNA expression upon citrate treatment (Figure 3.6). However, a 
functional consequence of increased BMP4 expression in mediating the hepcidin 
response to citrate could not be demonstrated. 
 To investigate what is the mechanism by which citrate stimulates the 
BMP/SMAD pathway it would be interesting to perform protein interactome analysis 
of the BMPR1A, SMAD4 or SMAD1 proteins in cells untreated and treated with 
citrate. This experiment would possibly reveal specific partners contributing to the 
induction of the BMP/SMAD pathway in response to citrate.  
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Metabolic changes triggered by elevated citrate levels may contribute to 
increased hepcidin mRNA expression 
 Citrate is a key metabolite which limits ATP production. When cells show 
elevated levels of ATP, citrate increases in the mitochondria, where it slows-down 
ATP production by inhibiting enzymes of the citric acid cycle [116-118] (see Section 
1.2.2 for more details). Following citrate increase in the mitochondria, citrate is 
exported to the cytosol (reviewed in [114, 115]). There, it exerts a negative feedback 
loop in that it binds to a rate-limiting enzyme for glycolysis (PFK1) ([164] and 
reviewed in [119]). When citrate is bound to PFK1, the rate of glycolysis is reduced 
and therefore ATP production is reduced. In the cytosol, citrate also allostericaly 
binds to the F1,6BPase to stimulate gluconeogenesis ([166, 167] and reviewed in 
[119]). Based on these findings I speculate that citrate might regulate hepcidin 
expression as a consequence of altered metabolism. In fact, recent reports show that 
gluconeogenic signals induce hepcidin expression in vitro and in mice [96] whilst the 
nutrient-sensing mTOR signaling pathway suppresses hepcidin expression [95].  
 To gain a molecular understanding of the functional link between citrate 
metabolism and hepcidin expression, future experiments will have to investigate the 
exact role citrate plays within the cell to regulate hepcidin mRNA expression. To 
address this, a metabolomics analysis of primary hepatocytes following citrate 
treatment would be crucial to better understand the metabolic changes induced by 
citrate that may be involved to activate hepcidin mRNA expression. Alternatively, 
isotope tracing could be performed. In this experimental approach, hepatocytes are 
treated with an isotope-labeled molecule of citrate (for example - deuterated sodium 
citrate) for different time-points and collected for mass-spectrometry analysis. The 
mass-spectrometry analysis would detect the metabolites derived from the isotope 
labeled citrate. This would allow to identify metabolic pathways the supplemented 
citrate is involved in.  
 Such experiments could provide a more in depth understanding as to why 
patients with metabolic diseases such as diabetes, obesity or metabolic syndrome, 
often present with perturbations in their body iron status. 
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Association between the BMP/SMAD signaling pathway and citrate metabolism 
 To adapt to metabolic changes, cells respond by regulating a variety of 
signaling pathways.  The mTOR pathway responds to the availability of glucose and 
amino acids, as well as the energy status of the cell, and regulates protein synthesis, 
autophagy, cell proliferation, mitochondrial function, lipogenesis, ketogenesis and 
glucose metabolism [168, 169]. The PI3K/AKT pathway regulates cellular oxygen 
consumption and glucose metabolism [170-172], whereas AMPK signaling senses 
increased intracellular ADP and promotes catabolic pathways to generate ATP while 
it inhibits anabolic pathways [173]. This work suggests that the BMP/SMAD 
signaling pathway, which is predominantly regulated during embryogenesis and in 
response to iron, could be controlled by alterations in citrate metabolism. This finding 
opens a new avenue for exploring how metabolism controls the BMP/SMAD 
signaling pathway or how this pathway can contribute to changes in cellular 
metabolism in the liver.  
 
Treatment of mice with iso-citrate results in the suppression of hepcidin  
 It has been reported that multiple-injections of iso-citrate in rats infected with 
peptidoglycan-polysaccharide polymers of Streptococcus pyogenes result in the 
improvement of anemia and in a suppression of hepcidin expression [174]. However, 
a similar study has shown that in mice infected with particles of heat-killed Brucella 
abortus, the amelioration of anemia and hepcidin suppression following iso-citrate 
injections is only transient [175]. Injections of iso-citrate in mice without an 
inflammatory stimulus were not reported to affect hepcidin mRNA expression [175]. 
My data show that citrate injections in mice up-regulate hepcidin expression. The 
differences in the regulation of hepcidin observed in these works could be due to 
citrate and iso-citrate being structurally different molecules with different fates within 
the cell. 
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Citrate as a therapeutic agent 
 Citrate has emerged as a therapeutic agent for treating polycystic kidney 
disease (PKD), kidney stones and cancer. Rats and mice with PKD treated with a 
combination of citric acid and other forms of citrate in drinking water for several 
months show signs of improved kidney function [176, 177]. In addition, rats with 
PKD treated with citrate until their death shows that citrate improves the survival of 
these rats compared to untreated rats with PKD [176]. Dent's disease is characterized 
by nephrocalcinosis (deposition of calcium salts in the renal parenchyma), 
nephrolithiasis (presence of stones in the kidneys or lower urinary tract) and 
progressive renal failure. Mice with Dent's disease fed with high citrate diet show no 
signs of stones, normal kidney function and no tubular atrophy, compared to mice fed 
with a normal diet [178]. In the clinical setting, one of the recommended therapies 
suggested by the American Urological Association to patients with low urinary citrate 
and/or calcium, uric acid and cystine stones is to intake a solution of potassium citrate 
for several months (https://www.auanet.org/education/guidelines/management-
kidney-stones.cfm). The intake of citrate is expected to replenish citrate levels in case 
they are low or to reduce the kidney and urinary tract stones by raising the urinary pH 
to an optimal level.  
 Due to its suppressive effect on glycolysis and ATP production, citrate has 
been proposed to be a drug with anti-tumor properties (reviewed in [114]). Citrate has 
been shown to highly induce apoptosis of human cancer cell lines when continuously 
administered in excess [149, 179]. Interestingly, few case studies of cancer patients 
described that the administration of citric acid every day for two weeks to several 
months improved their clinical features [180-183].  
 Since the injection of citrate in mice results in up-regulated hepcidin 
expression, it would be interesting to investigate whether patients undergoing 
prolonged citrate treatment (either as a therapeutic agent for kidney stones or as an 
anti-tumor drug) present altered hepcidin levels in the blood. This evidence would be 
particularly important to determine whether the management of hepcidin levels 
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should be considered along with the treatment of patients with citrate to prevent 
alterations of iron levels. 
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